Review

Neuroprotective potentials of marine algae and their bioactive metabolites: pharmacological insights and therapeutic advances

Md. Abdul Hannan 1,2, Raju Dash 1, Md. Nazmul Haque 3, Md. Mohibullah 4, Abdullah Al Mamun Sohag 2, Md. Ataur Rahman 5, Md Jamal Uddin 6,7, Mahboob Alam 1,8 and Il Soo Moon 1,*

1 Department of Anatomy, Dongguk University College of Medicine, Gyeongju 38066, Republic of Korea; hannanbau@gmail.com (M.A.H.); rajudash.bgtub@gmail.com (R.D.)
2 Department of Biochemistry and Molecular Biology, Bangladesh Agricultural University, Mymensingh-2202, Bangladesh; sohag2010bmb.sust@gmail.com (A.A.M.S.)
3 Dept. of Fisheries Biology and Genetics, Patuakhali Science and Technology University, Patuakhali-8602, Bangladesh; habib.332@gmail.com (M.N.H.)
4 Department of Fishing and Post Harvest Technology, Sher-e-Bangla Agricultural University, Sher-e-Bangla Nagar, Dhaka-1207, Bangladesh; mmohib08@gmail.com (M.M)
5 Center for Neuroscience, Korea Institute of Science and Technology (KIST), Seoul 02792, Republic of Korea; ataur1981rahman@hotmail.com (M.A.R.)
6 Graduate School of Pharmaceutical Sciences, College of Pharmacy, Ewha Womans University, Seoul, 03760, Republic of Korea; hasan800920@gmail.com (M.J.U.)
7 ABEx Bio-Research Center, East Azampur, Dhaka -1230, Bangladesh
8 Division of Chemistry and Biotechnology, Dongguk University, Gyeongju, 780-714, Republic of Korea mahboobchem@gmail.com (M.A.)
* Correspondence: moonis@dongguk.ac.kr; Tel.: +82-54-770-2414; Fax: +82-54-770-2447

Abstract: Beyond their significant contribution to the dietary and industrial supplies, marine algae are considered to be a potential source of some unique metabolites with diverse health benefits. The pharmacological properties, such as antioxidant, anti-inflammatory, cholesterol homeostasis, protein clearance and anti-amyloidogenic potentials of algal metabolites endorse their protective efficacy against oxidative stress, neuroinflammation, mitochondrial dysfunction, and impaired proteostasis which are known to be implicated in the pathophysiology of neurodegenerative disorders and the associated complications after cerebral ischemia and brain injuries. As was evident in various preclinical studies, algal compounds conferred neuroprotection against a wide range of neurotoxic stressors, such as oxygen/glucose deprivation, hydrogen peroxide, glutamate, amyloid β, or 1-methyl-4-phenylpyridinium (MPP⁺) and, therefore, hold therapeutic promise for brain disorders. While a significant number of algal compounds with promising neuroprotective capacity have been identified over the last decades, a few of them have had access to clinical trials. However, the recent approval of an algal oligosaccharide, sodium oligomannate, for the treatment of Alzheimer’s disease enlightened the future of marine algae-based drug discovery. In this review, we briefly outline the pathophysiology of neurodegenerative diseases and brain injuries for identifying the targets of pharmacological intervention, and then review the literature on the neuroprotective potentials of algal compounds along with the underlying pharmacological mechanism, and present an appraisal on the recent therapeutic advances. We also propose a rational strategy to facilitate algal metabolites-based drug development.

Keywords: seaweed; metabolites; neuroprotection; Alzheimer’s disease; Parkinson’s disease; ischemic stroke; computer-aided drug discovery
1. Introduction

Neurons and supporting cells of the brain encounter degenerative changes during physiological or pathological aging, ischemic stroke, or other brain injuries [1]. The degenerative brain disorders such as Alzheimer’s disease (AD) and Parkinson’s diseases (PD) are the consequence of pathological brain aging, which are characterized by the region-specific loss of neurons [2]. Globally, these diseases account for the major causes of dementia among the elderly [3]. Although the exact etiologies of these brain disorders are not revealed yet, they share some common pathophysiology, such as oxidative stress (OS), neuroinflammation, mitochondrial dysfunction, protein misfolding, and defective protein clearance system that, in turn, make these diseases complicated [4, 5]. Whereas, ischemic, traumatic, and other brain injuries, if not fatal, ensue secondary damage and constitute the appreciable causes of cognitive deficits among patients. Like neurodegenerative disorders, brain injuries also follow the same pathophysiology [6, 7]. Whatever the forms of dementia disorder, the current therapeutic option can only alleviate symptoms, rather than halting the disease progression. Moreover, current drugs are associated with multiple side effects. Considering the tremendous social and economic impact of these diseases, scientists are, therefore, paying research efforts to discover the potential therapeutic agents that can target disease pathogenesis without causing undesirable effects in patient’s health. Although synthetic drugs have some advantages such as easy to develop, naturally-derived compounds have received priority as they are relatively well-tolerated. Natural compounds have been claimed to show anti-inflammatory, antioxidant, and immunomodulatory effects [8]. Compounds showing multiple pharmacological effects offer a better solution for the remedy of neurological disorders with complex pathomechanism [9]. In the published literature, a significant quantity of natural products has been reported to show neuroprotective activity against a wide range of toxic insults [10, 11]. Some of them have shown therapeutic promise in preclinical studies [12] and clinical trials [13, 14].

Macroalgae, also known as seaweed, are among the highly abundant marine lives and potentially contribute to the renewable resources for food and industrial products [15-17]. Beyond this importance, algal metabolites, such as phenolics, alkaloids, terpenoids, carotenoids, phytosterols, and polysaccharides have attracted much attention to medicinal chemistry due to their structural uniqueness and functional diversity [17-19]. These biofunctional compounds have shown to provide neuroprotection in preclinical models of neurodegenerative diseases, ischemic stroke, brain trauma, diabetes, and obesity, among many others, owing to their antioxidant, anti-inflammatory, and immunomodulatory capacities [20-24]. Evidence suggests that algal metabolites, particularly fucoxanthin, fucosterol, and fucoidan could be potential leads for the development of therapy against CNS diseases [21, 25]. Although the algal metabolite-based drug discovery progresses very slowly, the discovery of sodium oligomannate and its conditional approval as an anti-AD drug [26] raises hope for the future development of potential therapeutic agents from marine algae.

Over the last decade, some excellent works reviewed the neuroprotective effects of marine algae and their metabolites [20-22, 25, 27-29]. However, some of these reviews limited their scope either to a single pathogenic mechanism such as neuroinflammation [21] or to categorical brain disorders such as AD or PD [21, 22, 25, 28, 29]. Others have reviewed literature published a decade or half a decade ago [22, 30]. Moreover, a few of them included reports that cover ischemic or other brain injuries. In the meantime, information on some potential algal compounds with neuroprotective activity has appeared in the scientific platform and there has also been significant progress in the clinical aspect. Addressing the knowledge gap and the possible limitations, offering a comprehensive review updating information on the neuroprotective effects of algal compounds and their therapeutic advances is timely. In this comprehensive review, we first briefly outline the pathobiology of neurodegenerative disorders, ischemic stroke, and traumatic brain injury and then provide pharmacological insights into the neuroprotective potentials of algal metabolites and highlight the recent progress in algae-based drug discovery. Finally, the rational strategy for algal compounds-based drug development has been discussed.
2. Pathophysiology of brain disorders

2.1. Neurodegenerative disorders (AD and PD)

Neurodegenerative disorders, including AD and PD, are of major public health concern and contribute to the prime causes of dementia among elderly people. The pathological hallmarks of AD include extracellular deposition of amyloid plaque and intraneuronal aggregation of neurofibrillary tangles (NFT) [31]. On the other hand, PD is characterized by the degeneration of dopaminergic neurons in the substantia nigra [31] with the pathological hallmark of intraneuronal aggregation of α-synuclein [32]. Although the exact pathophysiology of these brain disorders remains elusive, it has been demonstrated that OS, neuroinflammation, mitochondrial dysfunction, and protein misfolding largely contribute to their development [31]. OS and neuroinflammation are two considerably diverse disease processes in many pathological events [33]. Conversely, they are interplayed with each other in the entire disease process. Thus, inhibition of neuroinflammation may reduce the OS and vice versa.

OS is a pathological condition that develops when the production of reactive oxygen species (ROS) reaches an excessive level with lower efficiency of the cellular antioxidant defense system. Factors contributing to OS in the brain include excitotoxicity, depletion of the cellular antioxidant system, high susceptibility to lipid peroxidation, and high oxygen demand [34]. OS may lead to mitochondrial dysfunction, which further results in the excessive ROS generation and establishes a vicious cycle of OS [35, 36]. Moreover, the endoplasmic reticulum (ER), a site for protein folding, also takes part in ROS generation (Chaudhari et al., 2014). Protein misfolding in ER results in ER stress that is further responsible for ROS production [37]. ROS potentially contributes to the damage of cells through compromising the structure and function of biomolecules, including lipid peroxidation, protein oxidation, and deoxyribonucleic acid (DNA) damage (Kim et al., 2015), that eventually install neurodegeneration [32].

Neuroinflammation is another inevitable pathogenic factor of many neurodegenerative disorders [38]. Microglial activation is the major contributor to neuroinflammation [38]. A range of stimuli, including infection, trauma, toxic insults, and ischemia, may initiate microglial activation and disrupt the central nervous system (CNS) homeostasis [39, 40]. Once activated, microglia released pro-inflammatory and neurotoxic elements, like chemokines, cytokines, proteases, eicosanoids, ROS, and excitatory amino acids [39]. All of these elements are documented as a key player in neuroinflammation-associated OS as well as chronic neurodegeneration [41]. The deposition of misfolded proteins, as evident in the major NDD, can also induce an inflammatory response, which further causes OS [42].

Dysregulation of cholesterol homeostasis is also a critical factor that could induce OS and inflammation, and thus, may contribute to the pathogenesis of major brain disorders [43]. This disturbance in cholesterol metabolism in the brain is under the regulation of cholesterol transport mechanism. Liver X receptor beta (LXR-β), once activated, promotes multiple genes that regulate reverse cholesterol transport and thus confers neuroprotection [44, 45]. For instance, LXR-β agonist enhanced survival of dopaminergic neurons [46] and reduced the burden of mutant huntingtin [47] as well as promoted amyloid β (Aβ) clearance [48]. With the significant evidence of the implication of OS, neuroinflammation, and cholesterol dyshomeostasis in the pathobiology of neurodegenerative disorders, these pathological factors could be targeted for the development of potential therapeutics.

2.2. Ischemic stroke

Ischemic stroke is responsible for the second-highest death and disability across the world [49]. It is a pathological condition resulting from sudden occlusion of blood supply to the brain. If the patient survives, the affected brain areas accompany the secondary damage due to the restoration of blood flow and reoxygenation. This ischemia/reperfusion (I/R) event initiates mitochondrial ROS generation [50] and subsequent inflammatory response[51].
Mitochondrial ROS not only a crucial early driver of acute damage but also consider as an initiator of the consequence of a series of pathological features that develop over time following the reperfusion [52]. Initially, upon reperfusion, the burst of ROS production results in oxidative damage to mitochondria, thereby disrupts ATP production [53], which ultimately initiates neuronal cell death cascades [54]. ROS-mediated mitochondrial damage further installs the inflammatory response via the activation of microglia and astrocytes as well as influx of immune cells recruited by cytokines, adhesion molecules, and chemokines across the activated cerebral blood vessels [55]. This activation of the innate immunity triggers nuclear factor-kappa-B (NF-κB)-mediated production of numerous inflammatory cytokines that contribute to I/R injury [56]. Therefore, targeting OS and inflammatory response could be imperative to develop novel therapeutic strategies for the management of stroke.

2.3. Traumatic brain injury

Traumatic brain injury (TBI), an acquired brain injury caused by an external force or shock, is also considered to be a major cause of death globally, particularly in countries with a frequent incidence of traffic accidents [57]. Despite significant medical advances in recent times, the clinical outcomes of severely head-injured patients are not satisfactory.

As in ischemic stroke, mechanisms underlying the damages to the brain tissue with TBI are categorized into two classes: primary and secondary damages. Primary damage that irreversibly involves the mechanical damage of the skull and the brain has been complicated following the brain contusions, rupturing blood vessels, axonal injuries, and intracranial hemorrhages [58]. Whereas, the secondary damage causes neuronal degeneration over time due to various biochemical changes such as OS, excitotoxicity, inflammation, and mitochondrial dysfunction [59]. Following TBI, various OS markers such as lipid peroxidation products, oxidized protein moieties and DNA damage products are accumulated in the brain while antioxidants and enzymes molecules such as glutathione (GSH), glutathione peroxidase (GPx), glutathione reductase (GR), glutathione S-transferases (GST), superoxide dismutase (SOD) and catalase (CAT) are markedly declined (Rodriguez-Rodriguez, et al. [60]. It is suggested that treatment modalities associated with conferring neuroprotection on injured brain tissue and regeneration at the recovery stage of injured neurons have greater promise to restore at the site of brain injury following TBI.

3. Neuropharmacological potentials of marine algae and their metabolites: evidence from in vitro studies

Several compounds of diverse chemical classes have been reported from three major groups (brown, red, and green algae) of marine algae (Figure 1-4). Neuropharmacological properties of these compounds reported in various in vitro models are compiled (Table 1) and discussed in the following subsections. Besides bioactive compounds, macroalgae that have shown promising neuroactive potentials, and thus demand further attention are also mentioned.

3.1. Antioxidant activity

Marine algae-derived compounds have been reported to exhibit strong antioxidant property (Table 1), and thus may protect against oxidative damage. For example, fucoxanthin, a carotenoid from Sargassum siliquastrum, attenuated OS-induced DNA damage [61]. Fucoxanthin also prevented H2O2-induced DNA damage, which was associated with increased production of GSH, and expression of SOD [30]. Moreover, fucoxanthin promoted antioxidant defense in lipopolysaccharide (LPS)-activated BV-2 microglia by activating nuclear factor erythroid 2-related factor 2 (Nrf2)/ heme oxygenase-1 (HO-1) pathway and cell survival through activating cAMP-dependent protein kinase (PKA)/cAMP response element-binding (CREB) pathway and increasing BDNF secretion [62]. Fucosterol raised cellular antioxidant enzymes, such as SOD, GPx and CAT in experimental rats [63]. Jung and colleagues demonstrated that fucosterol prevented ROS production in tert-butyl hydroperoxide (t-BHP)-induced
RAW264.7 macrophages [64]. Also, fucosterol conferred protection from oxidative damage in HepG2 cells by raising GSH level [65] and in lung epithelial cells by increasing the expression of SOD, CAT, and HO-1, and nuclear translocation of Nrf2 [66]. Glycoprotein of *U. pinnatifida* improved SOD activity (53.45%) and inhibited xanthine oxidase (Xox) activity (82.05%) [67]. Diphlorethohydroxycarmalol and 6,6′-bieckol from *Ishige okamurae* exhibited antioxidant activity and reduced intracellular ROS level in RAW264.7 cells [68]. Sulfated polysaccharide fractions from *Porphyra haitanesis* showed antioxidant activity and inhibited Lipid peroxidation in rat liver microsome [69]. Porphyrin from *Porphyra yezoensis* showed superoxide anion and hydroxyl radical scavenging activity [70].

In addition, a great number of marine algae have shown antioxidant activity, including *Sargassum polycystum* and *Laurencia obtusa* [71], *Gelidium foliaceum* and *Codium duthieae* [72], to mention a few.

### 3.2. Anti-inflammatory activity

An appreciable number of algal compounds have been reported for anti-inflammatory activity (Table 1). Fucoxanthin, a common carotenoid of brown algae, attenuated inflammation, and OS in glial cells [30, 62]. In Aβ42-induced BV2 cells, fucoxanthin attenuated inflammatory response, which was manifested by decreased secretion of proinflammatory mediators, such as tumor necrosis factor-alpha (TNF-α), interleukin (IL)-6, IL-1β and prostaglandin E2 (PGE2) and reduced expression of inducible nitric oxide synthese (iNOS) and cyclooxygenase-2 (COX-2), and by lowering the phosphorylation of mitogen-activated protein kinase (MAPK) pathway [30]. In LPS-activated BV-2 microglia, fucoxanthin protected against neuroinflammation by lowering the expression of iNOS and COX-2 and reducing the secretion of inflammatory factors such as TNF-α, IL-6, PGE2, and nitric oxide (NO) that involved inhibition of protein kinase B (Akt)/NF-κB and MAPKs/activating protein-1 (AP-1) pathways [62].

The anti-inflammatory activity of fucosterol has recently been reviewed [73]. In brief, fucosterol exhibited anti-inflammatory action [74] and attenuated LPS-induced inflammation in RAW 264.7 macrophage [64]; [75] and alveolar macrophage [76]. Fucosterol also protected against LPS- or αβ-mediated neuroinflammation in activated microglial cells [77]. Several phlorotannins, such as dieckol [78], phlorofucofuroeckol A [79] and phlorofucofuroeckol B [80], 6,6′-bieckol [81] and 8,8′-bieckol [82] isolated from *Ecklonia* spp have been reported for their anti-inflammatory activities that involved suppression of NF-κB and MAPK pathways.

Fucoïdan, a sulfated polysaccharide attenuated inflammatory response in LPS-stimulated BV2 microglia by suppressing NF-κB and extracellular signal-regulated kinases (ERK)/MAPK/Akt pathways [83]. In another study, fucoidan decreased the generation ROS and TNF-α in LPS-induced primary microglia [84]. κ-Carrageenan oligosaccharides and its desulfated derivatives from red algae attenuated TNF-α production and showed anti-inflammatory activity in LPS-activated microglia [85]. Porphyrin from *Porphyra yezoensis* attenuated nitric oxide (NO) generation in LPS-stimulated RAW264.7 cells by suppressing iNOS expression [70, 86]. Treatment with sulfated oligosaccharides of *Ulva lactuca* and *Enteromorpha prolifera* reduced inflammatory factors and downregulated the expression of p53 and fork-head box protein O1 (FoxO1) genes and upregulated the expression of Sirt1 gene in SAMP8 mice [87]. Alginate-derived oligosaccharide inhibited the expression of inflammatory enzymes and secretion of proinflammatory cytokines in LPS/Aβ-induced BV2 microglia. This oligosaccharide also reduced the expression of toll-like receptor 4 and NF-κB [88]. Priming of LPS-stimulated primary microglia and astrocytes with seleno-polymannurinate (Se-PM) reduced the expression of inflammatory enzymes and the production of inflammatory mediators by suppressing NF-κB and MAPK signaling [89]. Sargachromenol isolated from *Sargassum micracanthum* attenuated inflammatory response in LPS-induced RAW 264.7 macrophages [90]. Kang and colleagues reported that sargauquinic acid of *Sargassum siliquastrum* suppressed inflammatory response in LPS-stimulated RAW 264.7 macrophages by downregulating NF-κB and c-JNK pathways [91]. Pretreatment of LPS-stimulated BV-2 microglial cells with floridoside inhibited inflammation by blocking p38/ERK phosphorylation [92]. Glycoprotein from *U. pinnatifida* (UPGP) reduced the expression of inflammatory enzymes and NO synthesis in LPS-stimulated RAW 264.7 macrophage [67]. Moreover, several algal...
Table 1 Summary on pharmacological effects, occurrence, effective dose, experimental model, cellular effects, potential pharmacological mechanism of algal metabolites

| Pharmacological effects | Compound (Class) | Algal source (if any) | Effective concentration | Experimental model (in vivo/in vitro) | Cellular effects/ significant findings | Signaling pathways involved | Pharmacological markers | Reference |
|-------------------------|------------------|-----------------------|-------------------------|--------------------------------------|----------------------------------------|--------------------------------|------------------------|-----------|
| **Antioxidant activity** | Fucoxanthin (carotenoids) | Sargassum siliquastrum | 50 and 100 μM | H₂O₂-induced cell damage in kidney fibroblast cells | Attenuates oxidative stress | n.d. | ↓ ROS level | [61] |
| Fucoxanthin | - | 5, 10 and 50 μM | H₂O₂-induced BV2 microglial cells | Antioxidation | Antioxidant pathway | ↓ ROS | ↑ SOD and GSH | [30] |
| Fucosterol, 3,6,17-trihydroxy-stigmasta-4,7,24(28)-triene and 14,15,18,20-diepoxyturbinarin (sterols) | Pelvetia siliquosa | A seven days-dose regimen at 30 mg/kg/day before carbon tetrachloride (CCl₄) administration | Rat model | Antioxidation | n.d. | ↑ SOD, CAT, and GPx | [63] |
| Fucosterol | Eisenia bicyclis, brown alga | 25, 50, 100, 200 and 400 μM | RAW 264.7 murine macrophages (t-BHP stimulated) | Protects against oxidative stress | n.d. | ↓ ROS generation | [64] |
| Fucosterol | Ecklonia stolonifera and Eisenia bicyclis; Brown algae | 25, 50 and 100 μM | tert-Butyl hydroperoxide- and tacrine-induced | Antioxidation | n.d. | ↓ ROS generation | ↑ GSH level | [65] |
| Pharmacological effects          | Compound (Class) | Algal source (if any) | Effective concentration | Experimental model (in *vivo*/*in vitro*) | Cellular effects/ significant findings | Signaling pathways involved | Pharmacological markers | Reference |
|----------------------------------|------------------|-----------------------|-------------------------|-------------------------------------------|----------------------------------------|-------------------------------|-------------------------|-----------|
|                                  | Fucosterol       | *Sargassum Binderi*; brown alga | 3.125, 6.25, 12.5, 25, 50, 100 μg mL\(^{-1}\) | HepG2cell injury model                   | Particulate matter-induced injury and inflammation in A549 human lung epithelial cells | Attenuates oxidative stress | ↓ ROS level ↑ SOD, CAT, and HO-1 in the cytosol, and NRF2 in the nucleus | [66].     |
|                                  | Glycoprotein     | *U. pinnatifida*       | SOD activity and Xox activity at a concentration of 5 mg/mL and 1 mg/mL, respectively | In vitro enzyme assay                    | -                                      | -                            | ↑ SOD and ↓ Xox          | [67].     |
|                                  | Sulfated oligosaccharides | *Ulva lactuca* and *Enteromorpha prolifera*; green algae | 150 mg/kg·day | Aging model (male senescence-accelerated prone (SAMP8) and male senescence resistant (SAMR1) mice) | antioxidant                           | n.d.                         | ↑ GSH, SOD, CAT, telomerase levels, ↑ Total antioxidant capacity, ↓ MDA and AGEPs | [87]      |
| Anti-inflammatory activity       | Fucoxanthin      | -                     | 5, 10 and 50 μM         | Aβ\(_{42}\)-induced BV2 microglia cells | Anti-inflammatory                      | MAPK pathway                 | ↓ iNOS, COX-2 ↓ TNF-α, IL-6, IL-1β, PGE\(_2\) | [30]      |
| Pharmacological effects | Compound (Class) | Algal source (if any) | Effective concentration | Experimental model (in vivo/in vitro) | Cellular effects/ significant findings | Signaling pathways involved | Pharmacological markers | Reference |
|-------------------------|-----------------|----------------------|------------------------|--------------------------------------|---------------------------------------|---------------------------|-------------------------|-----------|
|                         | Fucoxanthin     | -                    |                        | LPS-activated BV-2 microglia          | Anti-inflammation and antioxidation   | Akt/NF-κB and MAPKs/AP-1 pathways; PKA/CREB pathway | ↓ JNK, ERK, and p38 MAPK phosphorylation | [62]      |
|                         | Fucosterol      | E. bicylis; brown alga | 5–20 μM for NO         | RAW 264.7 murine macrophages (t-BHP200 Mm, LPS-1μM stimulated) | ↓ Inflammatory response               | ↓ NF-κB pathway           | ↓ NO production ↓ iNOS and COX-2 | [64]      |
|                         | Fucosterol      | U. pinnatifida       | 10, 25, or 50 μM       | LPS-induced RAW 264.7 macrophages and THP-1 human | ↓ Inflammatory response               | ↓ NF-κB pathway           | ↓ iNOS, TNF-α, and IL-6 ↓ DNA binding | [75]      |
| Pharmacological effects | Compound (Class) | Algal source (if any) | Effective concentration | Experimental model (in vivo/in vitro) | Cellular effects/significant findings | Signaling pathways involved | Pharmacological markers | Reference |
|-------------------------|-----------------|-----------------------|-------------------------|--------------------------------------|--------------------------------------|---------------------------|------------------------|-----------|
|                         | Fucosterol      | *Hizikia fusiformis*  | 1-10 μM                 | monocyte cell line                  | ↓ Inflammatory response              | n.d.                      | ↓ phosphorylation of NF-κB, MKK3/6 and MK2 | [74]      |
|                         | Fucosterol      | *Panida. australis*    | 0.004, 0.2, and 10 μM   | CoCl₂-induced hypoxia in keratinocytes | ↓ Inflammatory response              | n.d.                      | ↓ IL-6, IL-1β and TNF-α↓ pPI3K and pAkt and HIF1-α accumulation | [77]      |
|                         | Fucosterol      | *S. Binderi* brown alga | 3.125, 6.25, 12.5, 25, 50, 100 μg mL⁻¹ | Particulate matter-induced injury and inflammation in A549 human lung epithelial cells | ↓ Inflammatory response              | n.d.                      | ↓ COX-2, PGE₂, TNF-α and IL-6 | [66]      |
|                         | Dieckol (phlorotannin) | *E. cava*               | 50-300 μg/mL           | LPS-stimulated murine BV2 microglia | Anti-inflammation and antioxidation   | p-38 MAPK/NF-κB pathway     | ↓ NO and PGE₂;↓ iNOS and COX-2;↓ IL-1β and TNF-α;↓ ROS | [78]      |
|                         | Phloroglucinol, eckol, dieckol, 7-| *E. bicyclis* brown alga | 5-20 μM for NO         | LPS-stimulated RAW 264.7 | ↓ Inflammatory response              | ↓ NF-κB pathway            | ↓ NO production | [64]      |
| Pharmacological effects | Compound (Class) | Algal source (if any) | Effective concentration | Experimental model (in vivo/in vitro) | Cellular effects/ significant findings | Signaling pathways involved | Pharmacological markers | Reference |
|------------------------|------------------|-----------------------|-------------------------|-------------------------------------|--------------------------------------|---------------------------------|--------------------------|-----------|
| phloroeckol, phlorofucofuroec A and dioxinodehydroeckol (phlorotannin) | Phlorofucofuroecol A | E. stolonifera | 20 μM | LPS-activated BV2 and primary microglial cells | Anti-inflammation | 
- NF-κB, JNKs, p38 MAPK, and Akt pathways
- ↓ NO and PGE₂
- ↓ iNOS and COX-2
- ↓ IL-1β, IL-6 and TNF-α
- ↓ NF-κB activation and IkB-α degradation
- ↓ JNK, p38, and Akt phosphorylation | [79] |
| Phlorofucofuroecol B (phlorotannin) | Phlorofucofuroecol B | E. stolonifera | 10–40 μM | LPS-stimulated murine BV2 microglia | Anti-inflammation | 
- IkB-α/NF-κB and Akt/ERK/JNK pathways
- ↓ TNF-α, IL-1β and IL-6
- ↓ COX-2 and iNOS
- ↓ NF-κB activation and IkB-α degradation
- ↓ Akt, ERK, and JNK phosphorylation | [80] |
| 8,8'-bieckol (phlorotannin) | 8,8'-bieckol | E. cava | | LPS-stimulated primary macrophages and RAW 264.7 macrophages | Anti-inflammation; Protects mice from endotoxin shock | NF-κB pathway | ↓ NO and PGE₂
↓ iNOS mRNA and protein expression; ↓ IL-6; | [82] |
| Pharmacological effects | Compound (Class) | Algal source (if any) | Effective concentration | Experimental model (in vivo/in vitro) | Cellular effects/ significant findings | Signaling pathways involved | Pharmacological markers | Reference |
|-------------------------|-----------------|-----------------------|-------------------------|--------------------------------------|---------------------------------------|-----------------------------|----------------------|-----------|
|                         | 6,6′-bieckol (phlorotannin) | E. stolonifera | LPS-stimulated BV2 and murine primary microglial cells | Anti-inflammation | ↓ Transactivation of NF-κB and nuclear translocation of the NF-κB p65 subunit ↓ ROS ↓ ROS ↓ Transactivation of NF-κB and nuclear translocation of the NF-κB p65 subunit ↓ Akt, JNK and p38 MAPK phosphorylation | ↓ IκB-α/NF-κB and JNK/p38 MAPK/Akt pathways | ↓ COX-2 and iNOS; ↓ NO and PGE2; ↓ IL-6 | [81] |
|                         | Fucoidan (sulfated polysaccharide) | Brown seaweed | 25, 50, and 100 μg/ml | LPS-stimulated murine BV2 microglia | Anti-inflammation | NF-κB and JNK/p38 MAPK/Akt pathways | ↓ NO and PGE2; ↓ COX-2, iNOS and MCP-1; ↓ TNF-α and IL-1β; ↓ NF-κB activation; ↓ Akt, ERK, p38 MAPK and JNK phosphorylation | [83] |
| Pharmacological effects | Compound (Class) | Algal source (if any) | Effective concentration | Experimental model (in vivo/in vitro) | Cellular effects/ significant findings | Signaling pathways involved | Pharmacological markers | Reference |
|-------------------------|-----------------|----------------------|------------------------|-------------------------------------|--------------------------------------|-------------------------------|--------------------------|-----------|
|                         | Fucoidan        | -                    | 125 µg/mL              | LPS-activated primary microglia     | Anti-inflammation                    | n.d.                          | ↓ TNF-α and ROS           | [84]      |
|                         | κ-carrageenan oligosaccharides and desulfated derivatives | Red algae            |                        | LPS-activated microglia             | Anti-inflammation                    | n.d.                          | ↓ TNF-α                  | [85]      |
|                         | Sulfated oligosaccharides | U. lactuca and E. prolifera; green algae | 150 mg/kg/day | Aging model (male senescence-accelerated prone (SAMP8) and male senescence resistant (SAMR1) mice) | ↓ Inflammatory response              | n.d.                          | ↓ IFN-γ, TNF-α, and IL-6 | [87]      |
|                         | Alginate-derived oligosaccharide | Brown algae          | 50–500 µg/mL           | LPS/Aβ-stimulated BV2 microglia    | Anti-inflammation                    | TLR4/NF-κB signaling pathway   | ↓ NO and PGE₂; ↓ COX-2 and iNOS; ↓ TNF-α, IL-6 and IL-12; ↓ TLR4; ↑ NF-κB/p65 subunit translocation | [88]      |
|                         | Seleno-polymannuronate | Brown algae          | 0.8 mg/mL              | LPS-activated primary microglia and astrocytes; | Anti-inflammation                    | NF-κB and MAPK signaling       | ↓ NO and PGE₂; ↓ COX-2 and iNOS; ↓ TNF-α, IL-1β and IL-6; | [89]      |
| Pharmacological effects | Compound (Class) | Algal source (if any) | Effective concentration | Experimental model (in vivo/in vitro) | Cellular effects/significant findings | Signaling pathways involved | Pharmacological markers | Reference |
|-------------------------|------------------|-----------------------|-------------------------|---------------------------------------|-------------------------------------|-------------------------------------|--------------------------|----------|
|                         | Sargachromenol (plastoquinone) | Sargassum micracanthum | 30.2 μM (IC₅₀) | LPS-stimulated RAW 264.7 macrophages | Anti-inflammation | NF-κB signaling | ↑ IκB-α, p65, p38, ERK and JNK phosphorylation | [90] |
|                         | Sargaquinoic acid (plastoquinone) | Sargassum siliquastrum | LPS-stimulated RAW 264.7 macrophages | Anti-inflammation | NF-κB signaling | ↓ NO and PGE₂; ↓ COX-2 and iNOS; ↑ IκB-α | [91] |
| Floridoside (glycerol glycosides) | Laurencia undulate; red alga | 50 μM | LPS-stimulated murine BV2 microglia | Anti-inflammation | MAPK Signaling | ↓ NO, RO; ↓ iNOS; ↑ IκB-α; ↓ nuclear translocation of NF-κB; ↓ JNK1/2 MAPK | [92] |
| Glycoprotein | Ul. pinnatifida | COX-1 and COX-2 inhibition with IC₅₀ values of 53.03 ± 1.03 μg/mL and 193.35 ± 3.08 μg | LPS-stimulated RAW 264.7 macrophages | Anti-inflammation | n.d. | ↓ COX-1 and COX-2 ↓ NO | [67] |
| Pharmacological effects | Compound (Class) | Algal source (if any) | Effective concentration | Experimental model (*in vivo*/*in vitro*) | Cellular effects/ significant findings | Signaling pathways involved | Pharmacological markers | Reference |
|-------------------------|-----------------|-----------------------|-------------------------|---------------------------------|--------------------------------------|-----------------------------|-------------------------|----------|
|                         | Caulerpin (bisindole alkaloid) | *Caulerpa racemosa* | 100 µM/kg body wt | Capsaicin-induced ear edema and carrageenan-induced peritonitis | Inhibition of nociception | n.d. | n.d. | [93] |
|                         | Caulerpenyne (sesquiterpene) | *C. prolifera* and *C. racemosa* | 5.1 µM | lipoxygenase (LOX) enzyme activity assay | Inhibitory activity against LOX | - | Un-competitive type of inhibition | [94] |
|                         | Aquamin (multi-mineral complex) | *Lithothamnion corallioides*; red alga | | LPS-stimulated, glial-enriched primary cultures of rat cortex | Anti-inflammation | n.d. | ↓ TNF-α and IL-1β | [95] |
| Anticholinesterase activity | Fucosterol and 24-hydroperoxy 24-vinylcholesterol | *E. stolonifera* | IC\(_50\) values of 421.72 ± 1.43, 176.46 ± 2.51 µM, respectively | *In vitro* enzymatic assay | ↓ BChE activity | - | Selective inhibition of BChE | [96] |
|                         | Fucosterol | *Panida australis* | inhibition against AChE (10.99–20.71%) and BChE (4.53–17.53%) with concentrations ≤ 56 µM, | *In vitro* enzymatic assay | ↓ AChE and BChE activities | - | Nonselective cholinesterase inhibition | [77] |
| Pharmacological effects | Compound (Class) | Algal source (if any) | Effective concentration | Experimental model (*in vivo*/*in vitro*) | Cellular effects/ significant findings | Signaling pathways involved | Pharmacological markers | Reference |
|-------------------------|------------------|-----------------------|-------------------------|------------------------------------------|----------------------------------------|----------------------------|-------------------------|-----------|
|                         | Fucosterol       | *Sargassum horridum*  | -                       | *In vitro* enzymatic assay               | ↓ AChE activity                         | -                          | Non-competitive inhibition | [97]      |
|                         | Fucoxanthin      | -                     | IC₅₀ value 1.97 mM       | *In vitro* BChE activity assay           | ↓ BChE activity                         | Mixed inhibition type      |                         | [98]      |
|                         | Fucoxanthin      | Brown seaweed         | IC₅₀ value of 81.2 μM    | *In vitro* AChE activity assay; Molecular docking analysis | ↓ AChE activity                         | Fucoxanthin likely interacts with the peripheral anionic site within AChE | Non-competitive manner   | [99]      |
|                         | α-Bisabolol       | *Padina gymnospora*   | IC₅₀ value < 10 μg/ml    | *In vitro* enzymatic assay               | ↓ AChE and BChE activity                | -                          |                         | [100]     |
|                         | Glycoprotein     | *U. pinnatifida*       | AChE and BChE inhibitory activities with IC₅₀ values of 63.56 ± 1.86 and 99.03 ± 4.64, respectively | *In vitro* enzymatic assay               | ↓ AChE and BChE activity                | -                          |                         | [67]      |
|                         | Phloroglucinol, dibenz [1,4] dioxine-2,4,7,9-tetraol and eckol | *Ecklonia maxima*; Brown alga | IC₅₀ value: 76.70 to 579.32 μM | *In vitro* AChE activity assay | ↓ AChE activity | - | - | [101] |
|                         | Dieckol and phlorofucofuroecfol | *E. cava* | Ethanol-intoxicated memory | *In vitro* AChE activity assay | ↓ AChE activity | n.d. | ↑ Acetylcholine | [102] |
| Pharmacological effects | Compound (Class) | Algal source (if any) | Effective concentration | Experimental model (in vivo/in vitro) | Cellular effects/significant findings | Signaling pathways involved | Pharmacological markers | Reference |
|------------------------|-----------------|----------------------|-------------------------|--------------------------------------|-------------------------------------|-------------------------------|-------------------------|-----------|
| Anti-amyloidogenic and aggregation inhibition activity | Sargaquinoic acid and sargachromenol (plastoquinones) | Sargassum sagamianum | IC₅₀ value for anti-AChE: 23.2 and 32.7 μM, respectively; IC₅₀ value for anti-BChE of sargaquinoic acid 26 nm | Impairment in mice | | | | [103] |
| | (5E,10Z)-6,10,14-trimethylpentadeca-5,10-dien-2,12-dione and (5E,9E,13E)-6,10,14-trimethylpentadeca-5,9,13-trien-2,12-dione (Sesquiterpenes) | S. sagamianum | IC₅₀ values of 65.0 and 48.0, and 34.0 and 23.0 μM, respectively | In vitro ChE activity assay | Moderate inhibitory activity against AChE and BuChE | | | [104] |
| Anti-amyloidogenic and aggregation inhibition activity | Fucoxanthin | E. stolonifera and U. pinnatifida | ↓ β-secretase activity; Binding energy (-7.0 kcal/mol) | | | Mixed-type inhibition | | [105] |
| Fucoxanthin | - | 0.1–30 μM | Suppresses the formation of Aβ1-42 fibrils | | | | | [106] |
| Pharmacological effects | Compound (Class) | Algal source (if any) | Effective concentration | Experimental model (in vivo/in vitro) | Cellular effects/ significant findings | Signaling pathways involved | Pharmacological markers | Reference |
|-------------------------|------------------|-----------------------|-------------------------|--------------------------------------|----------------------------------------|-----------------------------------|-------------------------|-----------|
|                         | Fucoxanthin      | -                     | 2 μM                    | ThT assay                            | Inhibits Aβ1-42 fibril and aggregate formation | -                                 | -                       | [107]     |
|                         | Fucosterol       | *E. stolonifera* and *U. pinnatifida* | 10-100 μM (IC₅₀ value of 64.12 ± 1.0 μM) | *In vitro* enzyme assay - *In silico* analysis | ↓ β-secretase activity; Binding energy (-10.1 kcal/mol) | - | Noncompetitive inhibition | [105]     |
|                         | α-Bisabolol      | *Padina gymnospora*   | 5 μg/ml                 | Thioflavin T (ThT), Confocal laser scanning microscopy (CLSM) analysis, Transmission electron microscopy (TEM), Fourier transform infrared (FTIR) spectroscopic analysis and molecular dynamics simulation | prevents oligomers formation as well as disaggregates the matured fibrils | - | -                       | [108]     |
| Pharmacological effects | Compound (Class) | Algal source (if any) | Effective concentration | Experimental model (in vivo/in vitro) | Cellular effects/ significant findings | Signaling pathways involved | Pharmacological markers | Reference |
|-------------------------|----------------|-----------------------|------------------------|------------------------------------|----------------------------------------|-------------------------------|--------------------------|-----------|
| Cholesterol homeostasis and Aβ clearance activity | Glycoprotein | *U. pinnatifida* | IC$_{50}$ values of 73.35 ± 2.54 μg/mL | *In vitro* enzymatic assay | ↓ BACE1 activity | - | - | [67] |
| | Fucosterol | - | -100 and 200 μM (HEK293 cell cultures) -100 or 200 μM (macrophages and HepG2, H4IIE, and Caco2 cells) | -HEK293 cell cultures (Reporter system) -THP-1-derived macrophages Caco2 cells - HepG2 cells | Reverses cholesterol transport. No accumulation of triglyceride in HepG2 | n.d. | Dual-LXR agonist (LXR-$\alpha$ and LXR-$\beta$) ↑ ABCA1, ABCG1, and ApoE; ↑ Intestinal NPC1L1 and ABCA1; ↑ Insig-2a, that delays nuclear translocation of SREBP-1c | [109] |
| | Saringosterol | *Sargassum fusiforme* | -30 μM | -Luciferase reporter assay system -HEK293T, THP-1 monocytes, HepG2, RAW264.7, THP-1 macrophages and Caco-2 cells | n.d. | n.d. | Selective LXRβ agonist; ↑ ABCA1, ABCG1, and SREBP-1c | [110] |
| | Alginate-derived oligosaccharide | Marine brown algae | BV2 microglial cells | Microglial phagocytosis of Aβ | Toll-like receptor signaling | ↑ TLR4 | | [88]. |
| Pharmacological effects                                      | Compound (Class)                                                                 | Algal source (if any) | Effective concentration | Experimental model (in vivo/in vitro) | Cellular effects/significant findings | Signaling pathways involved | Pharmacological markers | Reference |
|-------------------------------------------------------------|---------------------------------------------------------------------------------|------------------------|--------------------------|---------------------------------------|--------------------------------------|-----------------------------|--------------------------|-----------|
| Monoamine oxidase inhibition and affinity to dopaminergic receptors | Phlorofucofuroeckol-A and dieckol (phlorotannin)                              | -                      |                          | \(\text{In vitro}\) enzyme assay and functional assay for GPCR screening; Docking analysis | ↓ hMAO activity; D3R and D4R stimulation | -                           | -                        | [111]     |
| Antiaging                                                   | Sulfated oligosaccharides                                                      | \(U.\ lactua\) and \(E. prolifera; green algae\) | 150 mg/kg/day            | Aging model (male senescence-accelerated prone (SAMP8) and male senescence resistant (SAMRI) mice) | Antioxidant and anti-inflammation | n.d.                        | ↑ GSH, SOD, CAT, telomerase levels, ↑ Total antioxidant capacity, ↓ MDA and AGEPs ↓ IFN-\(\gamma\), TNF-\(\alpha\), and IL-6 ↑ BDNF and ChAT; ↑ Sirt1, ↑ p53 and FOXO1 | [87]      |
| Fucosterol                                                  | \(Hizikia fusiformis\)                                                        | 50 µg/mL               | Culture model of \(C. elegans\) | Extends lifespan                      | ↑ Antioxidant mechanism                           | n.d.                        |                         | [112]     |
alkaloids such as caulerpin, racemosin A-C, and caulerins were shown to have anti-inflammatory activity [113].

In addition, several marine algae have been reported to show anti-inflammatory properties in various experimental models, for instance, 

Ecklonia cava [114], Myagropsis myagroides [115, 116], Sargassum serratifolium [117], and three Malaysian seaweeds (Padina australis, Sargassum polyctenum, and Caulerpa racemosa) [118] in LPS-stimulated murine BV2 microglia; Ulva conglobata in interferon gamma-induced BV2 cells [119]; Sargassum fulvellum [120], Sargassum horneri [121], Myagropsis myagroides [122, 123] in LPS-stimulated RAW 264.7 macrophage cells and Sargassum serratifolium in LPS-stimulated mouse peritoneal macrophages [124]. Owing to their capacity to modulate various inflammatory pathways, these algae and their respective compounds have shown encouraging effects in protecting various cell types from the inflammatory response.

3.3. Anticholinesterase activity

Currently prescribed anti-AD drugs are mostly based on the inhibition of cholinesterase activity. Several algal metabolites have been reported to inhibit cholinesterase activity (Table 1). For example, fucosterol and 24-hydroperoxy 24-vinylcholesterol isolated from E. stolonifera showed inhibitory activity against butyrylcholinesterase (BChE) [96]. Another study also demonstrated anticholinesterase activity of fucosterol [77]. Enzyme kinetics and computational analysis indicated a non-competitive mode of acetylcholinesterase (AChE) inhibition of fucosterol [97].

Fucoxanthin exhibited anti-BChE activity which was of mixed inhibition type [98]. Whereas Lin and colleagues demonstrated that fucoxanthin showed non-competitive inhibition against AChE [99]. α-Bisabolol from Padina gymnospora showed inhibition against cholinesterase activity [100]. Ulva pinnatifida-derived glycoprotein showed AChE and BChE inhibitory activities [67].

The IC50 values for phloroglucinol, dibenzo [1,4] dioxine-2,4,7,9-tetraol and eckol from Ecklonia maxima range from 76.70 to 579.32 μM, with later two compounds possessing the highest AChE inhibitory activity [101]. Dieckol and phlorofucofuroeckol exhibited a similar anti-AChE activity [102]. Sargachromenol acid and sargachromenol from Sargassum sagamianum have shown reasonable AChE inhibitory activity while the BChE inhibitory activity of sargachromenol acid is 1000-fold higher than for AChE [103]. Tyrosol and its derivative, 4-(1,2-dihydroxyethyl) phenol from Macrocystis angustifolia showed anti-AChE activity [125]. Meroterpenoids, such as sargahydroquinone acid, sargachromenol, and sargachromenol acid of S. serratifolium exhibited potent anti-AChE activity [126]. Among the phlorotannins tested, 8,8′-bieckol showed potent anti-AChE activity [127].

In addition, the extracts from some marine algae have shown anti-cholinesterase properties. These include Halimeda cuneata [72], Botryococcus braunii and Nannochloropsis oculata [128], Cystoseira tamariscifolia and Cystoseira nodicaulis [129], Ishige foliacea [130], and Asparagopsis taxiformis [131].

3.4. Anti-amyloidogenic and aggregation inhibition activity

As amyloid-β deposition is one the hallmark of AD, compounds that interfere with the generation of pathogenic Aβ and/or that inhibit its aggregation are of therapeutic importance. Several metabolites of marine algae have shown anti-amyloidogenic potentials (Table 1). For example, fucoxanthin at variant concentrations reduced the formation of Aβ42 fibril and Aβ1–42 oligomers, when co-incubated with Aβ1–42 monomers [106, 107]. Both studies also demonstrated that fucoxanthin has shown to inhibit Aβ aggregation [106, 107]. Inhibition of β-site amyloid precursor protein cleaving enzyme 1 (BACE1) with fucoxanthin was of a mixed-type [105]. Also, molecular docking analysis revealed a differential pattern of interaction [105]. Fucosterol showed a potential anti-BACE1 activity which was of noncompetitive type [105]. Supporting these findings, a recent in silico study also explained the binding and interaction pattern of fucosterol with BACE1 [132]. α-Bisabolol from Padina gymnospora prevented oligomers formation as well as disaggregated the matured fibrils [100]. Glycoprotein from U. pinnatifida exhibited anti-BACE1 activities with IC50 values of 73.35 ± 2.54 μg/mL [67]. Meroterpenoids, such as sargahydroquinone acid, sargachromenol, and sargachromenol acid of S. serratifolium exhibited potent anti-BACE1 activity [126]. Phlorotannins, such as eckol, dieckol, and 8,8′-bieckol from Ecklonia cava showed anti-BACE1 activity [127]. Olasehinde et
al. reported that four South African macroalgae such as *Gracilaria gracilis*, *Ulva lactuca*, *Ecklonia maxima*, and *Gelidium pristoides* exhibited anti-cholinesterase, anti-BACE1, and Aβ aggregation inhibitory activities, indicating these seaweed could be potential sources of anti-AD agents [29]. Ishige *foliacea* extract showed β-secretase inhibition property [130].

3.5. Cholesterol homeostasis and Aβ clearance activity

Some algal metabolites are known to activate LXR-β (Table 1), and thus help regulate cholesterol homeostasis and enhance Aβ clearance [48]. Fucosterol is a selective LXR-β agonist that upregulated several LXR target genes, such as *ATP-binding cassette transporter A1* (ABCA1), *ABCG1*, and *apolipoprotein E* (*ApoE*) [109, 110], suggesting that fucosterol could play a significant role in brain cholesterol homeostasis. Saringasterol, another selective LXR-β agonist isolated from *S. fusiforme*, activated the expression of similar LXR target genes in multiple cell lines [110]. Alginate-derived oligosaccharide isolated from marine brown algae promoted the microglial phagocytosis of Aβ, which is connected to the activation of toll-like receptor signaling [88]. As cholesterol imbalance and impaired protein clearance system significantly contribute to the pathogenesis of major neurological disorders, more efforts should, therefore, be paid to explore similar compounds that may help regulate cholesterol homeostasis and proteostasis.

3.6. Monoamine oxidase inhibition and affinity to dopaminergic receptors

Inhibition of MAO-A (monoamine oxidase-A), an enzyme that catalyzes oxidative deamination of neurotransmitters, such as dopamine, norepinephrine, and serotonin (5-HT), is a putative approach to raise the brain 5-HT level, thus alleviating the symptom of parkinsonism [133]. Seong and team screened the multi-target effects of three phlorotannins, i.e., phloroglucinol, phlorofucofuroeckol-A (PFF-A), and dieckol against human MAO-A and -B and various neuronal G-protein-coupled receptors (GPCRs). Of these, PFF-A exhibited a relatively higher inhibition against both hMAO isoforms, with greater selectivity toward hMAO-B (Table 1). Enzyme kinetics and computational findings indicated that PFF-A noncompetitively interacted with hMAOs and acted allosterically. In a functional assay for GPCR screening, dieckol and PFF-A showed a multi-target combination of D3R/D4R agonism and D1/5HT1A/NK1 antagonism [111].

3.7. Antiaging

Algal compounds that exhibited anti-aging effects (Table 1) could have therapeutical value for physiological as well as pathological brain aging. Sulfated oligosaccharides of *Ulva lactuca* and *Enteromorpha prolifera*, when treated in SAMP8 mice, increased the serum level of antioxidant molecules and total antioxidant capacity, and decreased the levels of malondialdehyde (MDA) and advanced glycation end products in the serum of experimental mice [87]. It has also been observed that these oligosaccharides decreased inflammatory factors, increased BDNF and choline acetyltransferase (ChAT) levels, and promoted the survival of hippocampal neurons. The underlying mechanisms involved the downregulation of *p53* and *FOXO1* genes and the upregulation of *Sirt1* gene [87]. *Caenorhabditis elegans*, when treated with fucosterol (at 50 µg/mL), survived longer compared to control, indicating that this algal compound might help extend life-span and thus might protect against premature aging [112]. Antioxidant, anti-inflammatory, and immunostimulatory properties of fucosterol were supposed to be involved in its pro-survival effect [134].

3.8. Neurotrophic activity

Compounds with neuritogenic potentials are promising to reconstruct damaged neuronal network which is a characteristic feature of neurodegeneration. Several algal metabolites have shown a promising neurite outgrowth promoting potentials in cell culture conditions (Table 2). Sargachromenol from *Sargassum macrocarpum* promoted nerve growth factor (NGF)-dependent neuronal differentiation of PC12D cells by activating cyclic AMP-mediated protein kinase and
Table 2 Neurotrophic activity of algal phytochemicals in vitro

| Compound                  | Algal origin (if any) | Dosage                     | Experimental model (in vivo/in vitro) | Cellular effects/ significant findings                       | Pharmacological markers                                                                 | References |
|---------------------------|-----------------------|----------------------------|---------------------------------------|-------------------------------------------------------------|-----------------------------------------------------------------------------------------|------------|
| Sargachromenol            | *Sargassum macrocarpum* (Brown alga, Japan) | ED$_{50}$ 9 μM (with 10 ng/ml NGF) | PC12D cells                          | NGF-dependent neurite outgrowth and survival                | ↑ PKA and MAPK1/2 ↑ PI3K                                                                | [135]      |
| Sargaquinoic acid         | *S. macrocarpum* (Brown alga, Japan) | 3 µg/ml (with 10 ng/ml NGF) | Cell differentiation                  | Cell differentiation                                        | Protein Kinase A and MAP Kinases-Mediated Signaling Pathways                           | [136]      |
| Vitamin B12 (chlorophyll-related analog to pheophytin) | *Sargassum fulvellum* (Brown alga, Japan) |                         | PC12 cells                          | Cell differentiation                                        | MAPK signal transduction pathway                                                      | [138]      |
| Pheophytin A              | *S. fulvellum* (Brown alga, Japan) | 3.9 µg/ml                  | PC12 cells                          | NGF-independent neurite outgrowth                            | ↑ PKA and MAPK1/2 ↑ PI3K                                                                | [137]      |
| Dimethylsulfoniopropionate | -                     | 7.4 mM                     | Neuronal N2a and glial OLN-93 cells | Process outgrowth; microtubule reorganization and bundling  | ↑ α-tubulin acetylation                                                                | [139]      |
| Fucoxanthin               | -                     | 0.1–2 μM                   | PC-12 cells                         | NGF-independent neurite outgrowth                            | n.d.                                                                                    | [107]      |
MAPK1/2 and supported their survival by activating phosphatidylinositol-3 kinase (PI3K) [135]. Sargarquinoic acid, another metabolite from *S. macrocarpum* promoted neuritogenesis in PC12D cells, that involved cooperation between two independent pathways, i.e., TrkA-MAPK pathway and adenylate cyclase-PKA pathway [136]. Ina and colleagues demonstrated that the neurodifferentiation of PC12 cells by phloretin a of *Sargassum fulvellum* required the presence of NGF and involved the activation of MAPK signaling pathway [137]. Vitamin B6, a chlorophyll-related analog to phloretin a, also stimulated NGF-dependent PC12 cell differentiation by MAPK signaling pathway [138].

Dimethylsulfoxonopropionate (DMSP) promoted neurite outgrowth and protected against TDA-induced cytotoxicity, involving the upregulation of Hsp32 and activation of the extracellular signal-regulated kinases 1/2 (ERK1/2) [139]. Fucoxanthin has shown to exhibit neurite outgrowth activity (15.7–31% of cells to develop neurite outgrowth) at much lower concentrations (0.1–2 μM), in the absence of NGF support, indicating that this marine carotenoid could a potential neurotrophic molecule [107]. *Gracilaria chorda* and its active compound arachidonic acid modulated spine dynamics, and potentiated functional synaptic plasticity of hippocampal neurons [140].

In addition, several marine algae have shown to promote neurite outgrowth. For example, *Sargassum macrocarpum* and *Jania adharens* showed neurotrophic potentials and promoted neuron-specific dendrites and axons from PC12D cells [141]. Two compounds, namely sargachromenol [135] and sargarquinoic acid [138], having neurite outgrowth potential were already isolated. *Porphyra yezoensis* and its compound taurine facilitated neuronal development and maturation of primary hippocampal neurons [142]. *Gelidium amansii* [143-146], *Sargassum fulvellum* [147], *Undaria pinnatifida* and *Saccharina japonica* [148], *Graecilaria chorda* [140, 149], and carrageenophyte *Kappaphycus alvarezi* [150-153] promoted neuronal morphology and functions. Of these, *G. amansii* that exhibited neuromodulatory potentials in several studies [143-146] could be the most promising candidate for further isolation of neurotrophic agents and thus expects special attention of natural product chemists.

3.10. Neuroprotective activity

Compounds that possess antioxidant, anti-inflammatory, anti-amyloidogenic, and anti-aggregation, cholesterol homeostasis, and protein clearance activities are expected to show potential neuroprotective effects. Congruently, the following metabolites isolated from marine algae have been reported to confer neuroprotection against a range of toxic stimuli (Table 3).

Several studies reported the neuroprotective activity of fucoxanthin. For example, fucoxanthin attenuated β-amyloid oligomer-induced [154] and H2O2-induced [155] apoptosis and OS in SH-SY5Y cells through activating pro-survival PI3K/Akt pathway and suppressing proapoptotic ERK pathway. Fucoxanthin-mediated protection against H2O2-induced apoptosis in primary cerebellar granule neurons also involved a similar neuroprotective mechanism [155]. Co-incubation of fucoxanthin with Aβ1–42 oligomers formed modified Aβ1–42 oligomers which were relatively less toxic to SH-SY5Y cells compared to Aβ1–42 oligomers, indicating that fucoxanthin-triggered structural modification of Aβ1–42 oligomers reduced their neurotoxicity [106]. Fucoxanthin, isolated from *Undaria pinnatifida*, also attenuated hypoxia/reoxygenation (H/R)-induced cellular injury in primary cortical [156] and hippocampal neurons [157]. Likewise, fucoxanthin suppressed oxygen-glucose deprivation/reperfusion (OGD/R)-induced neuronal apoptosis, via activating the Nrf2/ARE-1 signaling [158]. In the TBI model of mouse primary cortical neurons, fucoxanthin promoted neuronal survival against secondary injury and enhanced antioxidant enzymes such as HO-1 and NAD(P)H dehydrogenase [quinone] 1 (NQO-1) via activating Nrf2-ARE and Nrf2-autophagy pathways [159]. Fucoxanthin also attenuated both Aβ1-42- and H2O2-induced toxicity in PC12 cells [107].

Zonarol (ZO), a para-hydroquinone-type molecule from *Dictyopteris undulata* protected against OS in HT22 hippocampal and cerebrocortical neurons by activating the Nr2f2/ARE pathway [160]. It induced the expression of NQO-1, HO-1, and peroxiredoxin 4 (PRDX4) and thus helps regulate intracellular redox state [160]. α-Bisabolol, an active compound of *Padina gymnospora*, protected against Aβ-induced neurotoxicity in PC12 cells [108] and also in Neuro2a cells and transgenic C. elegans [161]. In PC12 cells, the rescuing effects of α-bisabolol against Aβ induced neurotoxicity were
similar to donepezil which is a currently prescribed anti-AD drug [108]. In Neuro2a cells, α-bisabolol exhibited inhibition against cholinesterase and β-secretase activity. In addition, α-bisabolol prevented apoptosis in Neuro2a cells by inhibiting the production of ROS and reactive nitrogen species (RNS) and reducing the expression of bcl-2-like protein (Bax) and caspase-3 [161]. In transgenic C. elegans Alzheimer’s model, α-bisabolol attenuated Aβ-induced proteotoxicity by decreasing the expression of angiotensin-converting enzyme 1 (ace-1), hsp-4, and Aβ [161]. The neuroprotective roles of fucosterol have been reviewed in our recent article [73]. In brief, fucosterol attenuated Aβ-induced neurotoxicity in hippocampal neurons [162] and SH-SY5Y cells [163].

Phlorotannins, a specialized group of tannins, particularly rich in brown algae, have shown significant neuroprotective effects in several neurotoxicity models. Liu and colleagues evaluated three phlorotannins, including 8,8'-bieckol, dieckol, and eckol for their neuroprotection against Aβ25-35-mediated cytotoxicity in PC12 cells [87]. Of these, dieckol showed maximum protection, although all were shown to suppress inflammatory response by inactivating the NF-κB pathway [87]. A similar study by Ahn and teams demonstrated that six phlorotannins, such as phloroglucinol, dioxinodehydroeckol, eckol, dieckol, phlorofucofuroeckol A, and 7-phloroeckol from Eisenia bicyclosis protected against Aβ-induced cytotoxicity by inhibiting ROS generation and Ca2+ release [164]. Also, in another study, phloroglucinol from E. cava suppressed Aβ1-42-provoked ROS accumulation in HT-22 hippocampal cell line [165]. Phloroglucinol also rescued the Aβ1-42-induced reduction of dendritic spine density and synaptic protein (synaptophysin and postsynaptic density) levels in primary cultures of rat hippocampal neuronal [165]. Kang and co-investigators isolated five phlorotannins, such as phloroglucinol, eckol, triphloroethol A, eckstolonol, and dieckol from E. cava that attenuated H2O2-induced oxidative damage in HT22 hippocampus neurons by lowering ROS production, lipid peroxidation and Ca2+ release [166]. Phlorofucofuroeckol attenuated glutamate-induced cytotoxicity and improved mitochondrial dysfunction in PC12 cells [168]. Preconditioned HT22 hippocampal neurons with diphlorethohydroxycarmalol (DPHC), a phlorotannin of Ishige okamurae, was able to escape H2O2-induced oxidative damage due to antiapoptotic, pro-survival, and antioxidant potentials of DPHC [167]. Eckmaxol, a phlorotannin of Ecklonia maxima, reduced Aβ-oligomer-induced neuronal apoptosis in SH-SY5Y cells by inhibiting GSK-3β and ERK pathways [169, 191].

Several studies have confirmed the neuroprotective capacity of algal polysaccharides, including fucoidan [192] and carrageenan. Fucoidan, a sulfated polysaccharide, attenuated Aβ1-42-induced neurotoxicity in rat cholinergic basal forebrain neurons [170]. It restored Aβ-induced decline in whole-cell currents, increased phosphorylation of protein kinase C (PKC), and showed antioxidant and anti-apoptotic effects [170]. Fucoidan protected H2O2-induced cell death in PC-12 cells by activating PI3K/Akt signaling pathway. The antioxidant, antiapoptotic and prosurvival effects of fucoidan could explain its neuroprotection capacity [172]. Fucoidan protected against Aβ25-35 and d-Gal-induced neurotoxicity in PC12 cells by reducing OS, suppressing apoptosis pathway, and promoting antioxidant defense [173]. Wu and colleagues reported that fucoidan suppressed intracellular Ca2+ responses by selective inhibition of N-methyl-D-aspartate (NMDA) receptors in cortical neurons and L-type Ca2+ channels in hippocampal neurons [175]. Three fucoidan extracts from Sargassum crassifolium attenuated H2O2-induced cytotoxicity in rat pheochromocytoma PC-12 cells [193]. In MPP+ PD model, fucoidan attenuated cytotoxicity in a dopaminergic neuronal precursor cell line (MN9D) [171, 174] by protecting lysosomes, reducing the expression of light chain 3-II (LC3-II), inhibiting the expression of cathepsin D (CatD)-Bax and the OS response [174]. Acidic oligosaccharide sugar chain attenuated Aβ-stimulated astrocytes conditioned medium-induced cytotoxicity in SH-SY5Y cells by mitigating oxidative damage, reducing inflammatory response, and preventing Ca2+ influx [177]. Also, κ-carrageenan-derived pentasaccharide (KCP) protected against
### Table 3 Neuroprotective activity of algal compounds in vitro and in vivo

| Compound (Class) | Algal origin (if any) | Effective concentration | Experimental model (in vivo/in vitro) | Cellular effects/significant findings | Signaling pathways involved | Pharmacological markers | References |
|------------------|-----------------------|-------------------------|--------------------------------------|--------------------------------------|-----------------------------|------------------------|------------|
| **In vitro experimental models** | | | | | | | | |
| Zonarol (para-hydroquinone sesquiterpene) | Dictyopteris undulate (Brown alga, Japan) | ED$_{50}$ = 0.22 µM (therapeutic index, defined as the ratio of ED$_{50}$ to LD$_{50}$, is 14.2 fold) | HT22 hippocampal neuronal cells (glutamate-induced oxidative stress) & Cerebrocortical neurons (glutamate or rotenone-induced oxidative stress) | Neuronal survival against oxidative stress | Nrf2/ARE pathway | † NQO-1, HO-1, and PRDX4 | [160] |
| Fucoxanthin (Undaria pinnatifida) | - | 0.15–1.5 µmol/L | Hypoxia/reoxygenation-induced neuronal injury | Neuronal survival against oxidative stress | n.d. | n.d. | [156] |
| Fucoxanthin | - | 20 µM | in vitro model of TBI (primary culture of mouse cortical neurons scratched manually) | Neuronal survival against secondary injury (oxidative stress) | Nrf2-ARE and Nrf2-autophagy pathways | † ROS † Beclin-1 (Atg6), LC3 (Atg8) and † p62 † Cleaved caspase-3 † Nrf2 nuclear translocation † HO-1 and NQO-1 | [159] |
| Fucoxanthin | - | 3 µM | β-Amyloid oligomer-induced | Neuronal survival against oxidative stress | PI3K/Akt and ERK Pathways | † ROS † pSer473-Akt and pSer9-GSK3β | [154] |
| Compound (Class)       | Algal origin (if any) | Effective concentration | Experimental model *(in vivo/in vitro)* | Cellular effects/ significant findings | Signaling pathways involved | Pharmacological markers | References |
|------------------------|-----------------------|-------------------------|----------------------------------------|----------------------------------------|-----------------------------|------------------------|------------|
| Fucoxanthin            | -                     | 1-3 μM                  | H₂O₂-induced toxicity in SH-SY5Y Cells and primary cerebellar granule neurons | Neuronal survival against oxidative stress | PI3K/Akt and ERK Pathways | ↓ pERK                 | [155]      |
| Fucoxanthin            | -                     | 0.3 μM                  | Fucoxanthin-modified Aβ₁-₄ oligomers-induced neurotoxicity in SH-SY5Y Cells | Neuronal survival                       | n.d.                        | n.d.                   | [106]      |
| Fucoxanthin            | -                     | 5 μM, 10 μM, and 20 μM  | Oxygen-glucose deprivation and reoxygenation (OGD/R) model of cultured neurons | Neuronal survival against oxidative stress | Nrf2/HO-1 signaling        | ↑ Nrf2 nuclear translocation ↑ HO-1 | [158]      |
| Fucoxanthin            | *Undaria pinnatifida* | 0.075 μg/mL            | H/R-induced excitotoxicity in primary hippocampal neurons | Neuronal survival against oxidative stress | n.d.                        | n.d.                   | [157]      |
| Fucoxanthin            | -                     | <2 μM (against Aβ1-42-mediated toxicity) 0.5–2 μM(H₂O₂-induced cytotoxicity | Aβ₁-42-mediated toxicity in PC12 cells | Cell survival                       | n.d.                        | n.d.                   | [107]      |
| Compound (Class) | Algal origin (if any) | Effective concentration | Experimental model \((in\,vivo/in\,vivo)\) | Cellular effects/ significant findings | Signaling pathways involved | Pharmacological markers | References |
|-----------------|-----------------------|-------------------------|----------------------------------------|-----------------------------------|----------------------------|-------------------------|------------|
| α-Bisabolol     | *Padina gymnospora*   | 5 µg/ml                 | Aβ\(_{25-35}\)-induced neurotoxicity in PC-12 cells | Antiaipoptosis                    | n.d.                       | n.d.                    | [108]      |
| α-Bisabolol     | *Padina gymnospora*   | 5 and 10 µg/ml          | Aβ\(_{25-35}\)-induced neurotoxicity in Neuro2a cells and transgenic C. elegans | Antioxidation; Antiapoptosis; Protection against Aβ\(_{-}\) induced proteotoxicity | Aβ mediated pathway | ↓ ROS, NOS ↓ Bax and caspase-3 ↓ ace-1, hsp-4 and Aβ | [161]      |
| Fucosterol      | *Ecklonia stolonifera*| 1–10 µM at 24 h before sAβ\(_{1-42}\) exposure (effective fucosterol conc. 5–10 µM) | sAβ\(_{1-42}\) (10 µM) - induced ER stress model of primary neurons | Attenuates Aβ\(_{-}\) mediated neurotoxicity | n.d.                       | ↑ TrkB-mediated ERK1/2 signaling ↓ GRP78 expression ↑ BDNF expression | [162]      |
| Fucosterol      | -                     | 0.0032 to 20 µM         | Aβ-induced cytotoxicity in SH-SY5Y cells | Reduces apoptosis in Aβ\(_{-}\) induced SH-SY5Y cells | n.d.                       | ↑ Ngb mRNA ↓ APP mRNA and intracellular Aβ levels | [163]      |
| Eckol, dieckol and 8,8′-bieckol | *Ecklonia cava*       | 1–50 µM                 | Aβ\(_{25-35}\)-stimulated PC12 cells | Antioxidation, anti-inflammation, anti-apoptotic properties | NF-κB pathway | ↓ COX-2, iNOS; ↓ TNF-α, IL-1β and PGE\(_{2}\) production; ↓ p38, ERK and JNK | [87]       |
| Phloroglucinol, eckol, triphloroethol A, | *Ecklonia cava*       | 50 µM                   | H\(_{2}\)O\(_{2}\)-induced oxidative stress in murine | ↓ Lipid peroxidation; | n.d.                       | ↓ ROS ↓ Ca\(^{2+}\) release | [166]      |
| Compound (Class) | Algal origin (if any) | Effective concentration | Experimental model (in vivo/in vitro) | Cellular effects/ significant findings | Signaling pathways involved | Pharmacological markers | References |
|------------------|-----------------------|-------------------------|--------------------------------------|---------------------------------------|-----------------------------|------------------------|------------|
| Eckstolonol, and dieckol | | | hippocampal HT22 cells | ↓ apoptosis | | | |
| Dihydroxyca rmalol | Ishige okamurae | 50 μM | H₂O₂-induced oxidative stress in murine hippocampal HT22 cells | Antioxidation; ↓ Lipid peroxidation; ↓ Apoptosis | n.d. | ↓ Bax ↑ Bcl-xL ↓ Poly (ADP-ribose) polymerase-1 (PARP) cleavage ↓ ROS ↓ Ca²⁺ release | [167] |
| Phloroglucinol, dioxinodehydroeckol, eckol, phlorofucofuroeckol A, dieckol, and 7-phloroeckol | Eisenia bicyclis | 2.5, 5, 10 and 20 μg/mL | Aβ peptide-induced toxicity in PC12 cells | Antioxidation | n.d. | ↓ ROS ↓ Ca²⁺ release | [164] |
| Phlorofucofuroeckol | Brown algae | 10 μM | Glutamate-induced cytotoxicity in PC12 | Antioxidation | n.d. | ↓ Caspase-3, -8, and PARP | [168] |
| Eckmaxol (phlorotannin) | Ecklonia maxima | 20 μM | β-amyloid oligomer -induced neuronal apoptosis in SH-SY5Y cells | ↓ Apoptosis | GSK-3β and ERK pathways | ↑ pGSK-3β ↓ pERK ↑ HO-1 | [169] |
| Fucoidan | - | 0.1–1.0 μM | Aβ-β induced neurotoxicity in rat cholinergic basal forebrain neurons | Restores Aβ-induced reduction in whole-cell currents | n.d. | ↑ pPKC ↓ ROS ↓ caspases 9 and 3 | [170] |
| Compound (Class) | Algal origin (if any) | Effective concentration | Experimental model (in vivo/in vitro) | Cellular effects/ significant findings | Signaling pathways involved | Pharmacological markers | References |
|------------------|----------------------|-------------------------|--------------------------------------|---------------------------------------|----------------------------|-------------------------|------------|
| Fucoidan (sulfated polysaccharide) | - | 0.1 and 1.0 mg/ml | MPP(+)−induced injury in MN9D cells | Antioxidation; Protects cellular injury | n.d. | n.d. | [171] |
| Fucoidan (sulfated polysaccharide) | - | 60 and 30 μg/mL | H2O2−induced apoptosis in PC12 cells | ↑ Cell viability; antioxidation | PI3K/Akt signaling | ↓ ROS; ↑ SOD and GPx activities; ↓ MDA; ↑ Bcl-2/Bax ratio; ↓ caspase-3; ↑ p-Akt | [172] |
| Fucoidan (sulfated polysaccharide) | - | 100, 200, 400 μg/mL | Aβ25-35 and d-Gal-induced neurotoxicity in PC12 cells | ↓ Apoptosis | Caspase-dependent apoptosis pathway | ↓ Cytochrome c release; ↓ Caspase activation; ↑ Livin and XIAP; ↑ SOD ↑ GSH | [173] |
| Fucoidan (sulfated polysaccharide) | - | 100 μM | MPP(+)−induced injury in dopaminergic precursor cell line(MN9D) cells | ↓ Apoptosis; Antioxidation; CatD-Bax signaling axis | ↓ LC3-II and CatD; ↓ Bax; ↑ SOD ↑ GSH | [174] |
| Fucoidan (sulfated polysaccharide) | Fucus vesiculosus Linn., brown alga | 0.5 mg/mL or 1.5 mg/mL | NMDA−induced Ca2+ responses in culture rat neurons | Suppresses the intracellular Ca2+ responses by selectively | n.d. | ↓ GluN1 mRNA and L-type Ca2+ channels, PR1/PR2 | [175] |
| Compound (Class)          | Algal origin (if any)                                                                 | Effective concentration | Experimental model (in vivo/in vitro)                        | Cellular effects/significant findings                                                                 | Signaling pathways involved | Pharmacological markers | References |
|--------------------------|----------------------------------------------------------------------------------------|-------------------------|-------------------------------------------------------------|--------------------------------------------------------------------------------------------------------|----------------------------|-------------------------|------------|
| Oligo-porphyrans         | Synthesized from porphyran (isolated from *Pyropia yezoensis*) through acidolysis reaction | 200 μg mL⁻¹             | 6-OHDA-induced cytotoxicity in PC12 cells                   | ↓ Apoptosis; Antioxidation; Anti-inflammation                                                          | PI3K/Akt/PKC pathway       | ↓ ROS; ↑ MMP            | [176]      |
|                          |                                                                                        |                         |                                                             |                                                                                                        |                            | ↑ SOD and GSH; ↑ Bcl-2/Bax ratio; ↓ caspase-3 and -9 ↑ p-Akt, p-PI3K, PKC ↑ DAT and TH ↓ TNF-α, IL-1β, and IL-6 |             |
| Acidic oligosaccharide   | *Echlonia kurome* Okam                                                                    | 50, 75, 100 μg mL⁻¹     | Inflammatory responses and cytotoxicity in SH-SY5Y cell line induced by Abeta-stimulated astrocytes conditioned medium | Oxidative stress                                                                                      | n.d.                       | ↓ TNF-α and IL-6        | [177]      |
| sugar chain              |                                                                                        |                         |                                                             |                                                                                                        |                            | ↓ Ca²⁺ influx            |            |
| Compound (Class)                                 | Algal origin (if any) | Effective concentration | Experimental model (in vivo/in vitro) | Cellular effects/ significant findings | Signaling pathways involved | Pharmacological markers | References |
|-------------------------------------------------|-----------------------|-------------------------|---------------------------------------|----------------------------------------|-------------------------------|--------------------------|------------|
| Racemosins A (bisindole alkaloid)               | *Caulerpa racemosa*, green alga | 10μM                    | Aβ2(5-35)-induced SH-SY5Y cell damage | ↑ Cell viability; ↓ apoptosis           | n.d.                          |                          | [178]      |
| Tramiprosate (small aminosulphonate compound)  | Red marine algae      | 50 mg/kg                | OGD- or NMDA-induced injury in NGF-differentiated PC12 cells and primary cortical neurons | Protects against neuronal injury       | n.d.                          |                          | [179]      |
| Dimethylsulfiniopropionate                      | -                     | 1 mg/mL                 | Tropodithietic acid-induced cytotoxicity in OLN-93 and N2a cells | Protects against neurotoxicity: Attenuates stress responses and mitochondrial damage | n.d.                          | ↓ ERK1/2 activation and HSP32 induction | [139]      |
| κ-carrageenan-derived pentasaccharide           | marine red algae      | 25, 50 or 100 μM        | Aβ25-35-induced neurotoxicity in SH-SY5Y cells | ↑ Cell viability; ↓ Apoptosis           | JNK signaling pathway          | ↓ Cleaved caspase 3 ↓ p-JNK | [180]      |

**In vivo experimental models**

| Fucoidan (sulfated polysaccharide)               | -                     | 25 mg/kg                | MPTP-induced animal model of Parkinsonism in C57/BL mice in vivo | ↓ Behavioral deficits; ↓ TH-positive neuronal loss | n.d.                          | ↑ Dopamine, DOPAC and HVA; ↑ Tyrosine hydroxylase; ↑ GSH; ↑ SOD, GPx, and catalase activity and | [171]      |
| Compound (Class) | Algal origin (if any) | Effective concentration | Experimental model (*in vivo*/*in vitro*) | Cellular effects/ significant findings | Signaling pathways involved | Pharmacological markers | References |
|----------------|----------------------|-------------------------|------------------------------------------|----------------------------------------|----------------------------|-------------------------|-----------|
| Fucoidan (sulfated polysaccharide) | - | 7.5 and 15 mg/kg body wt (intranigral injection) | LPS-induced neurotoxicity in rat | Ameliorates behavioral deficits, prevents the loss of dopaminergic neurons and inhibits the deleterious activation of microglia in the substantia nigra pars compacta | n.d. | ↓ CD11b | [84] |
| Fucoidan (sulfated polysaccharide) | - | 50, 100, 200 mg/kg | Aβ (1-40)-induced learning and memory impairment in rats | Ameliorates learning and memory impairment; ↓ oxidative stress; ↓ apoptosis | Antioxidation | ↑ ChAT, SOD and GPx activity; ↑ Ach; ↓ AchE activity; ↓ MDA; ↑ Bcl-2/Bax ratio; ↓ caspase-3 activity | [181] |
| Fucoidan (sulfated polysaccharide) | - | 100 and 200 mg/kg on day 2–6, 50 mg/kg on day 4–6 | d-Gal-induced cognitive dysfunction in mice | ↓ Apoptosis; ameliorate the learning and memory impairment | Caspase-dependent apoptosis pathway | ↑ Ach level and ChAT activity; ↓ AChE activity; ↑ SOD; ↑ GSH | [173] |
| Compound (Class)                      | Algal origin (if any) | Effective concentration | Experimental model (in vivo/in vitro) | Cellular effects/significant findings | Signaling pathways involved | Pharmacological markers | References |
|-------------------------------------|-----------------------|-------------------------|-------------------------------------|--------------------------------------|-----------------------------|-------------------------|-------------|
| Fucoidan (sulfated polysaccharide)  | -                     | 100–500 ng/ml           | Transgenic C. elegans AD model      | Alleviates the paralyzed phenotype; ↓ Abeta deposits | n.d.                        | ↑ Proteosomal activity (proteolysis); ↓ ROS | [182]       |
| Fucoidan-rich substances            | *E. cava*             | Polyphenol/fucoidan extract and mixture (4:6) | Trimethyltin-induced cognitive dysfunction model | Ameliorates learning and memory impairment | n.d.                        | ↓ ROS; ↑ MMP; ↓ BAX and cytochrome C release; ↓ Amyloid β production; ↓ Tau hyperphosphorylation | [183]       |
| Fucoidan                            | -                     | 50 mg/kg                | Transient global cerebral ischemia (tGCI) model of garbils | ↓ Oxidative stress and glial activation | n.d.                        | ↑ SOD1 and SOD2 | [184]       |
| Laminarin (polysaccharide)         | -                     | 50 or 100 mg/kg (i.p) for seven days before IR (5-min transient ischemia) surgery | Forebrain I/R injury in young gerbils (6 months) | ↓ Reactive gliosis (M1 microglia); ↓ Neuroinflammation | n.d.                        | ↓ IL-2 | [185]       |
| Laminarin (polysaccharide)         | Brown algae           | 50 mg/kg/day (i.p) for seven days before IR (5-24 months) | Forebrain I/R injury in aged gerbils (22–24 months) | ↓ Oxidative stress and neuroinflammation | n.d.                        | ↓ Superoxide anions and 4-hydroxy-2-nonenal (HNE) | [186]       |
| Compound (Class) | Algal origin (if any) | Effective concentration | Experimental model (in vivo/in vitro) | Cellular effects/ significant findings | Signaling pathways involved | Pharmacological markers | References |
|-----------------|-----------------------|-------------------------|---------------------------------------|---------------------------------------|-----------------------------|-------------------------|------------|
| Oligo-porphyran | Synthesized From porphyran (isolated from *Pyropia yezoensis*) through acidolysis reaction | 25 and 50 mg/kg | 6-OHDA-induced Parkinsonian mice model | ↓ Apoptosis; Ameliorates behavioral deficits | PI3K/Akt/Bcl-2 pathway | ↓ IL-1β and TNF-α ↑ SOD1 and SOD2 ↑ IL-4 and IL-13 | [187] |
| Porphyran (polysaccharide) | Degraded polysaccharide from *Pyropia haitanensis* | 75, 150, 300 mg/kg | Aβ1-40-induced mice AD model | Improved learning and memory deficits | n.d. | ↑ ChAT activity; ↓ AChE activity; ↑ Ach | [188] |
| Fucoxanthin | Brown seaweed | 50, 100, 200 mg/kg | Scopolamine-induced cognitive impairments in mice | Memory enhancement Anticholinesterase | n.d. | ↓ AChE and choline acetyltransferase ↑ BDNF | [99] |
| Fucoxanthin | - | 0.1–30 μM | Aβ oligomer-induced cognitive Memory enhancement, | n.d. | ↑ BDNF | [106] |
| Compound (Class) | Algal origin (if any) | Effective concentration | Experimental model (in vivo/in vitro) | Cellular effects/ significant findings | Signaling pathways involved | Pharmacological markers | References |
|------------------|-----------------------|-------------------------|--------------------------------------|---------------------------------------|---------------------------|-----------------------|------------|
| Fucoxanthin      | -                     | 5 μM, 10 μM, and 20 μM  | Middle cerebral artery occlusion (MCAO) rat model (cerebral ischemic/reperfusion (I/R) injury) | impairsments in mice attenuation of oxidative stress | n.d. | ↑ SOD activity ↓ ROS, MDA ↓ cleaved caspase-3 ↑ Bcl-2/Bax ratio | [158] |
| Fucoxanthin      | -                     | 100 mg/kg and 0.05 mmol/L | Traumatic brain injury (TBI) model | Anti-apoptosis, attenuation of oxidative stress, induction of autophagy | Nrf2-ARE and Nrf2-autophagy pathways | ↑ GPx ↓ MDA ↓ Cleaved caspase-3, PARP, cytosolic cytochrome c ↑ Mitochondrial cytochrome c ↑ Beclin-1 (Atg6), LC3 (Atg8) and ↓ p62 ↑ Nrf2 nuclear translocation ↑ HO-1 and NQO-1 | [159] |
| Fucosterol       | Ecklonia stolonifera   | 1–10 μM                 | sAβ1-42-induced memory dysfunction in aging rats | Ameliorates Aβ1-42-induced memory impairment | n.d. | ↑ TrkB-mediated ERK1/2 signaling ↓ GRP78 expression ↑ BDNF expression | [162] |
| Compound (Class) | Algal origin (if any) | Effective concentration | Experimental model (in vivo/in vitro) | Cellular effects/significant findings | Signaling pathways involved | Pharmacological markers | References |
|------------------|-----------------------|-------------------------|---------------------------------------|---------------------------------------|----------------------------|------------------------|------------|
| Dieckol and phlorofucofuroeckol | *Ecklonia cava* | PFF (0.2 and 2 mg/kg) and dieckol (1 and 10 mg/kg) | Alcohol-intoxicated memory-impaired mice | ↓ Acetylcholinesterase activity; reduces the inhibition of latency | n.d. | ↑ ACh | [102] |
| C-Phycocyanin | - | 200 mg/kg | Global cerebral ischemia/reperfusion (I/R) injury in gerbils | Reduces the infarct volume and improves the neurologic deficit score; Protects neurons, improves the functional outcome (locomotor behavior) and promotes survival | n.d. | ↓ MDA | [189] |
| Tramiprosate (small aminosulphonate compound) | Red marine algae | 50 mg/kg | Intraluminal filament model of MCAO | Reduces infarct volume | PSD95/nNOS signaling | Disruption of the interaction between PSD95 and nNOS; ↓ nNOS translocation | [179] |
| Sulfated agaran | *Gracilaria cornea*, red alga | 60 μg, single intrastriatal injection | Rat 6-hydroxydopamine Parkinson's disease model | ↓ Oxidative/nitrosative stress; Restores Behavioral | n.d. | ↑ DA, DOPAC and HVA; ↓ 5-HT; ↓ NO2/NO3 and TBARS | [190] |
| Compound (Class) | Algal origin (if any) | Effective concentration | Experimental model (*in vivo/in vitro*) | Cellular effects/ significant findings | Signaling pathways involved | Pharmacological markers | References |
|------------------|-----------------------|-------------------------|-----------------------------------------|--------------------------------------|-----------------------------|-------------------------|------------|
|                  |                       |                         |                                         | deficits and locomotor performance; improves weight | ↑ GSH; ↓ p65, IL-1β and iNOS; ↑ BDNF |                         |            |
Aβ25-35-induced neurotoxicity in SH-SY5Y cells by regulating c-Jun N-terminal kinase (JNK) signaling pathway [180]. Oligo-porphyran (OP), an acid hydrolytic product of porphyran (a polysaccharide of Pyropia yezoensis) attenuated 6-OHDA-induced cytotoxicity in PC12 cells by activating PI3K/Akt/PKC pathway that involved anti-apoptotic, antioxidant and anti-inflammatory signals [176].

Sargaquinoic acid identified from Sargassum macrocarpum promoted cell survival and neurite regeneration and attenuated H2O2-induced OS in PC12D cells [194]. Racemosins A, a bisindole alkaloid from Caulerpa racemose attenuated Aβ2(5-35)-induced damage in SH-SY5Y cells [178]. Tramiprosate, a small aminosulphonate compound of red marine algae attenuated OGD- or NMDA-induced injury in PC12 cells and primary cortical neurons [179] by disrupting the interaction between PSD95 and nNOS and inhibition of nNOS translocation [179]. Potentials of tramiprosate against AD has also been reviewed elsewhere [195, 196]. Dimethylsuloniopropionate protected against tropodithietic acid-induced cytotoxicity in OLN-93 and N2a cells by lowering the activation of ERK1/2 and induction of HSP32 [139]. Phycoerythrin-derived peptide isolated from Pyropia yezoensis promoted survivability of frontal cortical neuron by activating TrkB receptor-ERK1/2 signaling and attenuating ER stress in rat prefrontal cortex [197] and attenuated glutamate-induced ER stress and senescence of rat primary hippocampal neurons [198].

In addition, extracts from several marine algae have shown neuroprotective activity in various in vitro models. The neuroprotective algae include Ulva conglobata that protected against glutamate-induced neurotoxicity in murine hippocampal HT22 cell line [119], Botryococcus braunii and Nannochloropsis oculata against H2O2-induced cytotoxicity in dopaminergic SH-SY5Y cells [128], Padina pavonica, Sargassum muticum, Saccorhiza polyschides, Codium tomentosum, and Ulva compressa [199], and Bifurcaria bifurcata [200] against 6-hydroxidopamine-induced cytotoxicity in neuroblastoma cells, Cystoseira tamariscifolia and Cystoseira nodicaulis against H2O2-induced cytotoxicity in SH-SY5Y cells [129], Australian microalgae against Aβ 1-42-induced neurotoxicity in PC-12 cells [201], Ishige foliacea against H2O2- or Aβ-induced cell death in human neuroblastoma SH-SY5Y cells [130], and Gracilariopsis corda [202] and Gelidium amansii [143] against H/R-induced oxidative damage in primary hippocampal neurons, indicating that these algae could offer some potential compounds with encouraging neuroprotective activity, and, therefore, demand further investigation.
Figure 1. Chemical structure of sterols (A) and plastoquinones (B) of marine algae.
Figure 2. Chemical structure of phlorotannin of marine algae
Figure 3. Chemical structure of alkaloids (A), sesquiterpenes (B) and polysaccharides (C) of marine algae.
4. Neuropharmacological potentials of marine algae and their metabolites: evidence from in vivo studies

The neuroprotective effects of some potential algal compounds that were reported in the in vitro conditions have successfully been translated into animal models (Table 3), suggesting that these compounds could be potential candidates for further evaluation in the clinical trials.

Fucoidan is one of the algal compounds that has shown strong neuroprotection in several animal models. In PD model of C57/BL mice, fucoidan ameliorated MPTP-induced behavioral deficits, probably by elevating dopamine and its metabolites levels and increasing tyrosine hydroxylase expression [171]. Also, fucoidan inhibited MPTP-induced lipid peroxidation and restored antioxidant capacity [171]. Similarly, fucoidan also improved behavioral capacity, by attenuating the loss of dopaminergic neurons and inhibited the deleterious activation of microglia in the substantia nigra pars compacta in LPS-induced neurotoxicity [84]. In Aβ-induced rodent AD model, fucoidan ameliorated impaired memory, by reversing the decreased activity of ChAT, SOD, and GPx, increased activity of AChE, and rectifying the imbalance between apoptosis and prosurvival signals [181]. Fucoidan improved d-Gal-induced cognitive impairment in mice by mitigating OS and attenuating the caspase-dependent apoptosis pathway [173]. Wang and colleagues demonstrated that the supplementation of fucoidan alleviated Aβ-induced paralyzed phenotype in a transgenic C. elegans AD model [182]. Fucoidan reduced Aβ accumulation, probably by promoting proteasomal activity [182]. In another study, fucoidan-rich substances from Ecklonia cava improved trimethyltin-induced cognitive dysfunction by inhibiting Aβ production and Tau hyperphosphorylation [183]. Fucoidan also attenuated transient global cerebral ischemic injury in the gerbil hippocampal CA1 area through mitigating glial activation and oxidative stress [184].

Laminarin, another polysaccharide of brown algae, has shown to protect I/R injury in gerbil models. Intraperitoneal injection of laminarin (50 mg/kg) following 5 min I/R attenuated reactive gliosis (anti-inflammatory) in the hippocampal CA1 of young gerbils [185]. A similar study following the same experimental protocol, but with aged gerbils, showed that laminarin (50 mg/kg) attenuated ischemia-induced death of pyramidal neurons in the hippocampal CA1 of aged gerbils [186]. This neuroprotective effect of laminarin is attributed to its antioxidant and anti-inflammatory properties [186]. Oligo-porphyran, a synthetic product of porphyran (Pyropia yezoensis) ameliorated behavioral deficits in 6-OHDA-induced Parkinsonian mouse model by protecting dopaminergic loss and activating PI3K/Akt/Bcl-2 pathway that involved cellular signaling of anti-apoptosis and antioxidation [187]. Zhang and colleagues demonstrated that porphyran from Pyropia haitanensis improved the Aβ1-40-induced learning and memory deficits probably by elevating cerebral acetylcholine level [188].

Fucoxanthin is another significant algal metabolite that was found effective in a wide range of brain dysfunction (such as AD, ischemic stroke, and traumatic brain injury). Fucoxanthin ameliorated scopolamine-induced [106] and Aβ oligomer-induced [99] cognitive impairments in mice, possibly by inhibiting AChE activity and OS, modulating ChAT activity, and increasing BDNF expression. Fucoxanthin ameliorated cerebral ischemic/reperfusion (I/R) injury, improved the neurologic deficit score, and downregulated the expression of apoptosis-linked proteins in brain samples [188]. Fucoxanthin also attenuated traumatic brain injury that involved the Nrf2-ARE and Nrf2-autophagy pathways-dependent neuroprotective mechanism [159].

Fucoxisterol co-infusion ameliorated sAβ42-induced cognitive deficits in aging rats by modulating BDNF signaling [162]. Dieckol and phlorofucofuroeckol raised the brain level of acetylcholine by inhibiting AChE and reduced the inhibition of latency in ethanol-intoxicated memory-impaired mice [102]. Yang and co-investigators demonstrated that stereotoxic injection of chloroglucinol promoted synaptic plasticity and improved memory impairment in 5XFAD (Tg6799)
mice [165]. In a later study, the same group reported phloroglucinol (orally administered)-mediated amelioration of cognitive dysfunction that involved a reduction in the amyloid β peptide burden and pro-inflammatory mediators and restoration of reduction in the dendritic spine density in the hippocampus of 5XFAD mice [203]. Phlorofucofuroeckol improved ischemic brain damage in rat MCAO model [168]. C-Phycocyanin improved the functional outcome and survival of gerbils on global cerebral I/R injury [189]. The in vitro neuroprotective effect of tramiprosate has been translated into in MCAO rat model in which it improved functional recovery following ischemic stroke [179]. Sulfated agaran, a sulfated polysaccharide from *Gelidium corneum* attenuated oxidative/nitrosative stress and ameliorates behavioral deficits in rat 6-hydroxydopamine Parkinson’s disease model [190]. It increased levels of dopamine, 3,4-Dihydroxyphenylacetic acid (DOPAC), GSH, and BDNF, decreased serotonin (5-HT) and thiobarbituric acid reactive substances (TBARS) levels, and decreased the expression of p65, IL-1β, and iNOS [190]. Glycoproteins isolated from *Caposiphon fulvescens* ameliorated aging-induced spatial memory deficits by attenuating GSK-3β-mediated ER stress in rat dorsal hippocampus [204] and promoted probiotics-induced cognitive improvement in aged rat model [205]. *Gracilaria chorda* and its active compound arachidonic acid, given independently through oral route for 10 days, improved scopolamine-induced memory impairment in mice [140].

In addition, extracts from several marine algae have shown to either ameliorate memory impairment or enhance cognition in various in vivo models. For instance, *Gelidiella acerosa* attenuated Aβ25-35-induced cytotoxicity and memory deficits in mice [206], *Sargassum swartzii* improved memory functions in rats [207], *Ishige foliacea* [130] and *Undaria pinnatifida* [208] ameliorated scopolamine-induced memory deficits in mice. Also, some marine algae have shown to attenuate ischemic injury in stroke models. For example, *Ecklonia cava* ameliorated transient focal ischemia in rat MCAO model [209].

**5. Recent progress on the development of marine algae-based neurotherapeutics**

An algal oligosaccharide, sodium oligomannate, recently received conditional approval in China for improving cognitive function in patients with mild to moderate AD [26]. In preclinical studies, sodium oligomannate conferred neuroprotection against Aβ-induced neurotoxicity in human neuroblastoma cells [210] and ameliorated memory dysfunction in 5XFAD transgenic mouse model [211]. Sodium oligomannate can cross the blood-brain barrier through glucose transporter (GLUT1) and inhibits Aβ fibril formation and destabilizes the preformed fibrils into nontoxic monomers [211]. Although the complete mechanism of pharmacological actions remains unclear, sodium oligomannate harnessed neuroinflammation and thus ameliorated memory impairment by suppressing gut dysbiosis and the associated phenylalanine/isoleucine accumulation [211]. In a phase IIa pilot study in patients with AD, there was an elevation of Aβ1–42 levels in the cerebrospinal fluid (CSF) following sodium oligomannate treatment, suggesting a significant role in Aβ clearance into CSF [212]. There was a differential reduction in the cerebral glucose metabolic rate (CMRglu) in various brain regions following sodium oligomannate in clinical trials [212]. While in a phase IIa trial, the CMRglu in left orbitofrontal gyrus, left precuneus, right posterior cingulate gyrus, and right hippocampus were found to be low; in phase III trial, the lower rate was reported in superior parietal gyrus, inferior parietal gyrus, angular gyrus, and anterior wedge [212]. However, this newly approved drug lacks some advanced information like global data of effectivity and thus requires a large-scale global trial before it receives approval from the Food and Drug Administration (FDA).

**6. Algal metabolites-based drug discovery and design**

While a significant quantity of active compounds has been isolated from marine algae and added to the compound databases [213-218] every year, it is disappointing that very few of them have access to clinical trial and the success rate is also not very satisfactory. In this context, the current strategy of drug development requires a reformation with the inclusion of some modern approaches, such as virtual screening and network pharmacology. The system biology approach along with in silico study
constitutes a potential computation tool that can better explain how a biologically effective compound interacts with the signal molecules of various cellular pathways.

Recent multitarget drugs have been designed by analyzing the 3D structure of already characterized compounds and crystal structure of target protein molecules. This information is focused on the virtual design of new chemical entities that include more than one biological function in a single molecule [219]. This approach is also known as target fishing, which identifies not only interacting proteins but also potential off-targets, and thus helps to understand polypharmacology, pharmacokinetics, and toxicity in the early stages of drug discovery [220]. For example, using in silico target fishing approach, Hannan and colleagues elucidated pharmacological mechanism of fucosterol-mediated neuroprotection and demonstrated that fucosterol showed interaction with potential targets, including LXR, TrKb, GR, Toll-like receptor (TLR) 2/4 and BACE1 [132]. Computational methods involving target screening are classified based on their principle including pharmacophore screening, shape screening, and reverse docking. When the target is available in the crystal structure, target fishing can be accomplished by a reverse docking approach, while in the absence, pharmacophore or shape screening can be used to find the relevant target by comparing pharmacophoric feature or shape of the compound, taking information from protein-ligand binding databases [221]. In this effort, several natural product databases containing compound target interactome are available nowadays including, SuperNatural [222], TCMID [223], TCMSp [224], and many others [225, 226], however, not many are dedicated to marine algae [213-215]. Although algal metabolites show structural diversity and redundancy, the mentioned databases could still be available for network pharmacology to get insight into the disease-modifying mechanisms. Following this in silico approach, Vitale et al identified caulerpin as a PPAR agonist which was confirmed by both in vitro and in vivo assays [227]. In a reverse way, virtual screening through molecular docking analysis could be an alternative to find out potent hits from a large chemical library for a single target.

Compared to experimental high throughput screening, virtual screening, either by ligand or structure-based approach, can deliver the shorten cycle of hit discovery, with higher success hit rates. Furthermore, a structure-based approach consisting of molecular docking, receptor-based pharmacophore modeling together with molecular dynamics simulations and MM/PB(GB)SA approaches not only predict protein-ligand interaction but also provide a detailed binding mechanism, protein dynamics, and also highlights structure-activity relationship (SAR) for future drug design [228]. Several recent studies are adopting molecular docking techniques to analyze detailed protein-ligand interaction for marine bioactive compounds. For example, Jung et al. employed molecular docking studies to predict comparative binding interaction of monoamine oxidase (MAO) with fucoxanthin, a carotenoid from Eisenia bicyclis, where they revealed fucoxanthin as a reversible competitive hMAO inhibitor, binds strongly to the enzyme, following hydrogen bonding and hydrophobic interactions [229]. A similar approach has been applied to elucidate the interaction of fucosterol and fucoxanthin with BACE1 while analyzing BACE1 enzyme inhibition by fucosterol and fucoxanthin. Here binding interaction analysis by molecular docking identified that the presence of hydroxyl group in fucosterol and fucoxanthin is important for BACE1 inhibition; by which, both compounds interacted with Lys224 residue; Gly11 and Ala127 of the active site, respectively [105]. Interestingly, fucoxanthin was also identified as a dopamine agonist, where molecular docking study suggested that it formed H-bonding with Ser196 and Asp115 of D4 receptor, and Ser196 and Thr115 residues of D3 receptors [230]. The same group also identified some bromophenols derivatives as D3R and hD4R antagonists and studied the interaction and binding pattern by molecular docking [231].

In addition, several studies employed virtual screening to identify potent lead molecules from the database of seaweed metabolites. For instance, Florest et al. identified sigma-2 (σ2) receptor binding ligand by using both structure and ligand-based screening [232]. However, less effort has been deployed to develop marine natural product libraries, although significant studies so far have reported many compounds isolated from marine sources by large populations in the world. In this exertion, Davis et al. developed a chemical library of the natural compounds from marine algae,
SWMD, comprising of 1110 metabolites, isolated from brown algae (266), green algae (33), and red algae (811) along with their physical and chemical properties [213]. Nevertheless, the information including experimentally-determined quantitative activity data and source information for more marine algal metabolites is still needed to facilitate computational based approaches in the exploration of marine compounds for future drug discovery.

7. Safety issues on marine algae-derived compounds

As a popular food material in East Asian countries, including Japan, Korea and China, seaweed are consumed without reported toxicity. However, the concern is that seaweed may sometime accumulate a considerable amount of heavy metals, such as cadmium, arsenic, mercury, and lead, and even some essential microelements such as iodine and iron [233]. It is, therefore, essential to conduct appropriate safety evaluation for seaweed. More importantly, while it is of safety concern during therapeutic development, the toxicity profile of seaweed-derived compounds needs to be thoroughly investigated. Safety information on algal metabolites is limited. However, toxicity profiles of algal polysaccharides have been reported by several studies. Observations from both in vitro and in vivo studies satisfied the non-toxic behavior of fucoidan irrespective of algal sources [234]. Fucoidan isolated from Undaria pinnatifida and Laminaria japonica was found to be safe in animal models given at very high oral doses [235-238]. Clinical studies also demonstrated the non-toxic health benefits of fucoidan in humans [239, 240]. Safety evaluation studies on carrageenan suggest that sub-chronic or chronic feeding of this food-grade polysaccharide did not induce any toxic effect [241]. Moreover, dietary supplementation of carrageenan was not associated with carcinogenicity, genotoxicity, or reproductive defects [241]. Another study reported that no toxicological response was induced when iota-carrageenan was administered through the intranasal route [242]. Several studies also investigated toxicity of fucoxanthin and suggested that this carotenoid was safe and caused no visible toxicity in experimental subjects [243-245]. The toxicity profiles of some other marine metabolites have been recently reviewed [24]. As sufficient toxicological profiles of other potentially bioactive metabolites are lacking, they should be investigated with appropriate experimental models.

8. Conclusion and future perspectives

The current review highlights several neuropharmacological attributes, such as antioxidant, anti-inflammatory, anti-cholinesterase, anti-amyloidogenic, antiaging, protein clearance, cholesterol homeostasis, and neuritogenic capacity of algae-derived metabolites that underlie their neuroprotective functions against a wide range of neurotoxic stimuli (Figure 1). The neuroprotective effects of marine algae and their metabolites do not necessarily depend on a single attribute, rather on the synergism of multiple of these pharmacological properties. As neurodegenerative disorders involve complex pathogenic mechanisms, they could better be managed with a single compound targeting two or more of the pathogenic mechanisms or multiple compounds with the complementary mechanism of action. In this context, algal compounds, such as fucoxanthin, fucosterol, and fucoidan that are known to target multiple pathogenic mechanisms could be potential candidates for future drug development. Besides, several metabolites, including laminarin, porphyran, saringasterol, α-bisabolol, and phlorotannins that exhibited encouraging neuroprotective roles, also deserve further attention.

Although neuroactive compounds were isolated from a range of algae, seaweed species under Phaeophyceae yields the highest number of compounds. However, species from other groups, for example, Gelidium amansii under Rhodophyceae that exhibited significant neuromodulatory effects, also could offer some promising metabolites. Moreover, a large number of species remain unexplored. While degenerating brains experience disruption of synaptic connectivity, compounds with neuritogenic capacity may potentially enhance the regeneration of damaged processes. Therefore, compounds, both neuroprotective and neurotrophic, are equally important. However, in contrast to neuroprotective compounds that potentially support neuronal survival, a few compounds
showing neurite outgrowth potential have been discovered in marine algae. Compounds, including those that
Figure 1. A scheme highlighting the pathophysiology of neurodegenerative disorders and post-ischemic consequence along with indicating the underlying mechanism of neuroprotective action of algal compounds. The numeric symbols indicate the points of pharmacological action that include (1) inhibition of cytokine secretion from activated microglia by fucoxanthin, fucosteroid, fucoidan, dieckol, phlorofucofuroeckol and dieckol, κ-carrageenan, floridoside and seleno-polymannarate, (2) attenuation of inflammatory response via inhibition of NF-κB pathway by eckol, dieckol and 8,8’-dieckol, (3) priming of antioxidant defense system via activation of Nrf2/ARE pathway (blocking interaction between Nrf2 and Keap1) by fucoxanthin, fucoidan and zonarol, (4) Reduction of apoptosis via inhibiting pro-apoptotic JNK/Erk pathway by dimethylsulfoxonipropionate and κ-carrageenan-derived pentasaccharide, (5) Inhibition of glutamate-induced Ca²⁺ influx via blocking extrasynaptic GluN2B by fucoidan and tramiprosate, (6) Activation of BDNF-dependent pro-survival pathway via inducing PI3K/Akt or TrkB/ERK signaling by fucoxanthin and fucosterol, (7) Attenuation of I/R-injury via preventing excitotoxic depolarization by C-phycocyanin, (8) Inhibition of nNOS sequestration by tramiprosate, (9) proteasomal degredation by fucoidan, (10) Induction of autophagy/mitophagy by fucoxanthin, (11) anticholinesterase activity by fucoidan, fucoxanthin, dieckol and phlorofucofuroeckol, (12) anti-amyloidogenesis via blocking β-secretase activity by fucoidan, fucosterol and glycoprotein, and (13) Aβ-clearance via enhancing the transcription of ApoE and ABC transporters genes by fucosterol, saringasterol and alginate-derived oligosaccharide. 

NF-κB/p50, nuclear factor kappa-light-chain-enhancer of activated B cells; Nrf2, nuclear factor erythroid 2-related factor 2; ARE, antioxidant respose element; IκB, inhibitor of NF-κB; Keap1, Kelch-like ECH-associated protein 1; JNK, c-Jun N-terminal kinases; GluN2B, N-methyl D-aspartate receptor subtype 2B; PI3K, phosphoinositide 3-kinases; Akt, protein kinase B; MEK1/2, mitogen-activated protein kinase kinase; Akt, protein kinase B; MEK1/2, mitogen-activated protein kinase kinase; ERK, extracellular signal-regulated kinases; TrkB, tropomyosin receptor kinase B; CREB, cAMP-response element binding protein; CRE, cAMP response elements; BDNF, Brain-derived neurotrophic factor; AChE, acetylcholinesterase; ACh, acetylcholine; ABCA1, ATP-binding cassette transporter A1; nNOS, neuronal nitric oxide synthase; ROS, reactive oxygen species; ψ, mitochondrial membrane potential.

have already shown neuroprotective ability as well as those that have not yet been explored, therefore, need to be screened for their ability to promote neurite extension.

Despite a sizable collection of algae-based natural products with distinct neuroprotective functions, only sodium oligomannate has emerged as a successful drug for AD. This review, therefore, calls for intensive research on other potential compounds to translate the preclinical findings into clinical models. Also, the factors that are responsible for the failure of a clinical trial need to be carefully reviewed. For example, the bioavailability of a candidate drug in the brain, including its ability to cross BBB remains one of the barriers to therapeutic success. If the ADME (absorption, distribution, metabolism, and excretion) properties of a preclinically effective compound sufficiently guarantee its drug-likeliness, it is highly likely that the compound may succeed in clinical trials. That’s why, the ongoing strategy requires a rational reformation incorporating modern approaches, such as virtual screening and system biology to strengthen the algae-based drug development process. The computational study will provide some crucial information on the ADME properties of potential leads and its interaction and binding affinity to molecular targets while system biology knowledge will identify the potential interaction of target molecules and cellular signaling pathways at the systemic level. With the constant discovery of new compounds, all these strategies will accelerate the designing and development of algae-based future drugs.

Author Contributions: Conceptualization, M.A.H. and I.S.M.; Resources, all authors; Writing – Original Draft Preparation, all authors; Writing – Review & Editing, M.A.H., M.N.H., M.M., AAMS, M.J.U. and I.S.M.; Visualization, M.A.H. and R.D.; Supervision, I.S.M.. All the authors have read and approved this manuscript.

Funding: Our research and publications have been supported by the Basic Science Research Program (2018R1A2B6002232 to I.S.M.) through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning. MAH and MAR wish to acknowledge the NRF for Korea Research
Fellowship (#2018H1D3A1A01074712 to M.A.H. and #2017H1D3A1A02013844 to M.A.R) funded by the Ministry of Science, ICT and Future Planning.

Acknowledgements: This article is dedicated to Professor Yong-Ki Hong of Pukyong National University, Korea on the occasion of his retirement. Professor Hong has spent most of his academic and research career working on marine biotechnology, including the enrichment of macroalgaebased functional metabolites and the development of value-added products.

Conflicts of interest: The authors declare no conflict of interest.

References
1. Chi, H.; Chang, H.-Y.; Sang, T.-K., Neuronal Cell Death Mechanisms in Major Neurodegenerative Diseases. *Int J Mol Sci* 2018, 19, (10), 3082.
2. Vasili, E.; Dominguez-Meijide, A.; Outeiro, T. F., Spreading of α-Synuclein and Tau: A Systematic Comparison of the Mechanisms Involved. 2019, 12, (107).
3. Zhong, X.; Wang, J.; Carlsson, C.; Okonkwo, O.; Zetterberg, H.; Li, L., A Strategy for Discovery and Verification of Candidate Biomarkers in Cerebrospinal Fluid of Preclinical Alzheimer's Disease. *Frontiers in molecular neuroscience* 2018, 11, 483.
4. Ganguly, G.; Chakrabarti, S.; Chatterjee, U.; Saso, L., Proteinopathy, oxidative stress and mitochondrial dysfunction: cross talk in Alzheimer's disease and Parkinson's disease. *Drug design, development and therapy* 2017, 11, 797-810.
5. Verri, M.; Pastoris, O.; Dossena, M.; Aquilani, R.; Guerrieri, F.; Cuzzoni, G.; Venturini, L.; Ricevuti, G.; Bongiorno, A. I., Mitochondrial Alterations, Oxidative Stress and Neuroinflammation in Alzheimer's Disease. *International Journal of Immunopathology and Pharmacology* 2012, 25, (2), 345-353.
6. Jayaraj, R. L.; Azimuth, S.; Beiram, R.; Jalal, F. Y.; Rosenberg, G. A., Neuroinflammation: friend and foe for ischemic stroke. *Journal of neuroinflammation* 2019, 16, (1), 142.
7. Islam, M. T., Oxidative stress and mitochondrial dysfunction-linked neurodegenerative disorders. *Neurological research* 2017, 39, (1), 73-82.
8. Yahfoufi, N.; Alsadi, N.; Jambi, M.; Matar, C., The Immunomodulatory and Anti-Inflammatory Role of Polyphenols. *Nutrients* 2018, 10, (11), 1618.
9. Leon, R.; Garcia, A. G.; Marco-Contelles, J., Recent advances in the multitarget-directed ligands approach for the treatment of Alzheimer's disease. *Medicinal research reviews* 2013, 33, (1), 139-89.
10. Angeloni, C.; Vauzour, D., Natural Products and Neuroprotection. *Int J Mol Sci* 2019, 20, (22), 5570.
11. Rehman, M. U.; Wali, A. F.; Ahmad, A.; Shakeel, S.; Rasool, S.; Ali, R.; Rashid, S. M.; Madkhali, H.; Ganaie, M. A.; Khan, R., Neuroprotective Strategies for Neurological Disorders by Natural Products: An update. *Curr Neuropharmacol* 2019, 17, (3), 247-267.
12. Kim, J.; Lee, H. J.; Lee, K. W., Naturally occurring phytochemicals for the prevention of Alzheimer's disease. *2010, 112, (6), 1415-1430.
13. Turner, R. S.; Thomas, R. G.; Craft, S.; van Dyck, C. H.; Mintzer, J.; Reynolds, B. A.; Brewer, J. B.; Rissman, R. A.; Raman, R.; Aisen, P. S.; Alzheimer's Disease Cooperative, S., A randomized,
double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. *Neurology* 2015, 85, (16), 1383-1391.

14. Salehi, B.; Stojanović-Radić, Z.; Matejić, J.; Sharifi-Rad, M.; Anil Kumar, N. V.; Martins, N.; Sharifi-Rad, J., The therapeutic potential of curcumin: A review of clinical trials. *Eur J Med Chem* 2019, 163, 527-545.

15. Leandro, A.; Pereira, L.; Gonçalves, A. M. M., Diverse Applications of Marine Macroalgae. 2020, 18, (1), 17.

16. Wells, M. L.; Potin, P.; Craigie, J. S.; Raven, J. A.; Merchant, S. S.; Helliwell, K. E.; Smith, A. G.; Camire, M. E.; Brawley, S. H., Algae as nutritional and functional food sources: revisiting our understanding. *Journal of Applied Phycology* 2017, 29, (2), 949-982.

17. Holdt, S. L.; Kraan, S., Bioactive compounds in seaweed: functional food applications and legislation. *Journal of Applied Phycology* 2011, 23, (3), 543-597.

18. Peng, J.; Yuan, J.-P.; Wu, C.-F.; Wang, J.-H., Fucoxanthin, a marine carotenoid present in brown seaweeds and diatoms: metabolism and bioactivities relevant to human health. *Mar Drugs* 2011, 9, (10), 1806-1828.

19. Salehi, B.; Sharifi-Rad, J.; Seca, A. M. L.; Pinto, D. C. G. A.; Michalak, I.; Trincone, A.; Mishra, A. P.; Nigam, M.; Zam, W.; Martins, N., Current Trends on Seaweeds: Looking at Chemical Composition, Phytopharmacology, and Cosmetic Applications. *Molecules* 2019, 24, (22), 4182.

20. Alghazwi, M.; Kan, Y. Q.; Zhang, W.; Gai, W. P.; Garson, M. J.; Smid, S., Neuroprotective activities of natural products from marine macroalgae during 1999–2015. *Journal of Applied Phycology* 2016, 28, (6), 3599-3616.

21. Barbance, M. C.; Malaguti, M.; Giusti, L.; Lucacchini, A.; Hrelia, S.; Angeloni, C., Anti-Inflammatory Activities of Marine Algae in Neurodegenerative Diseases. *Int J Mol Sci* 2019, 20, (12), 3061.

22. Barbosa, M.; Valentão, P.; Andrade, P. B., Bioactive compounds from macroalgae in the new millennium: implications for neurodegenerative diseases. *Mar Drugs* 2014, 12, (9), 4934-72.

23. Cornish, M. L.; Critchley, A. T.; Mouritsen, O. G., Consumption of seaweeds and the human brain. *Journal of Applied Phycology* 2017, 29, (5), 2377-2398.

24. Rengasamy, K. R. R.; Mahomoodally, M. F.; Aumeeruddy, M. Z.; Zengin, G.; Xiao, J.; Kim, D. H., Bioactive compounds in seaweeds: An overview of their biological properties and safety. *Food and Chemical Toxicology* 2020, 135, 111013.

25. Schepers, M.; Martens, N.; Tiane, A.; Vanbrabant, K.; Liu, H. B.; Lütjohann, D.; Mulder, M.; Vanmierlo, T., Edible seaweed-derived constituents: an undisclosed source of neuroprotective compounds. *Neural regeneration research* 2020, 15, (5), 790-795.

26. Syed, Y. Y., Sodium Oligomannate: First Approval. *Drugs* 2020, 80, (4), 441-444.

27. Pangestuti, R.; Kim, S. K., Neuroprotective effects of marine algae. *Mar Drugs* 2011, 9, (5), 803-18.

28. Huang, C.; Zhang, Z.; Cui, W., Marine-Derived Natural Compounds for the Treatment of Parkinson’s Disease. *Mar Drugs* 2019, 17, (4).
29. Olasehinde, T. A.; Olaniran, A. O.; Okoh, A. I., Macroalgae as a Valuable Source of Naturally Occurring Bioactive Compounds for the Treatment of Alzheimer's Disease. *Marine drugs* **2019**, 17, (11).

30. Pangestuti, R.; Vo, T.-S.; Ngo, D.-H.; Kim, S.-K., Fucoxanthin Ameliorates Inflammation and Oxidative Responses in Microglia. *Journal of Agricultural and Food Chemistry* **2013**, 61, (16), 3876-3883.

31. Hou, Y.; Dan, X.; Babbar, M.; Wei, Y.; Hasselbalch, S. G.; Croteau, D. L.; Bohr, V. A., Ageing as a risk factor for neurodegenerative disease. *Nature reviews. Neurology* **2019**, 15, (10), 565-581.

32. Singh, A.; Kukreti, R.; Saso, L.; Kukreti, S., Oxidative Stress: A Key Modulator in Neurodegenerative Diseases. *Molecules* **2019**, 24, (8), 1583.

33. Uddin, M. S.; Kabir, M. T.; Mamun, A. A.; Barreto, G. E.; Rashid, M.; Perveen, A.; Ashraf, G. M., Pharmacological approaches to mitigate neuroinflammation in Alzheimer's disease. *Int Immunopharmacol* **2020**, 84, 106479.

34. Sivandzade, F.; Prasad, S.; Bhalariao, A.; Cucullo, L., NRF2 and NF-κB interplay in cerebrovascular and neurodegenerative disorders: Molecular mechanisms and possible therapeutic approaches. *Redox Biol* **2019**, 21, 101059-101059.

35. Castelli, V.; Benedetti, E.; Antonosante, A.; Catanesi, M.; Pitari, G.; Ippoliti, R.; Cimini, A.; d’Angelo, M., Neuronal Cells Rearrangement During Aging and Neurodegenerative Disease: Metabolism, Oxidative Stress and Organelles Dynamic. **2019**, 12, (132).

36. Wang, X.; Wang, W.; Li, L.; Perry, G.; Lee, H.-g.; Zhu, X., Oxidative stress and mitochondrial dysfunction in Alzheimer’s disease. *Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease* **2014**, 1842, (8), 1240-1247.

37. Gerakis, Y.; Hetz, C., Emerging roles of ER stress in the etiology and pathogenesis of Alzheimer’s disease. *The FEBS journal* **2018**, 285, (6), 995-1011.

38. Guzman-Martinez, L.; Maccioni, R. B.; Andrade, V.; Navarrete, L. P.; Pastor, M. G.; Ramos-Escobar, N., Neuroinflammation as a Common Feature of Neurodegenerative Disorders. *Front Pharmacol* **2019**, 10.

39. Yanuck, S. F., Microglial Phagocytosis of Neurons: Diminishing Neuronal Loss in Traumatic, Infectious, Inflammatory, and Autoimmune CNS Disorders. *Front Psychiatry* **2019**, 10.

40. Sofroniew, M. V., Astrocyte barriers to neurotoxic inflammation. *Nat Rev Neurosci* **2015**, 16, (5), 249-63.

41. Hernandes, M. S.; D’Avila, J. C.; Trevelin, S. C.; Reis, P. A.; Kinjo, E. R.; Lopes, L. R.; Castro-Faria-Neto, H. C.; Cunha, F. Q.; Britto, L. R.; Bozza, F. A., The role of Nox2-derived ROS in the development of cognitive impairment after sepsis. *J Neuroinflammation* **2014**, 11, 36.

42. Liu, Z.; Zhou, T.; Ziegler, A. C.; Dimitrion, P.; Zuo, L., Oxidative Stress in Neurodegenerative Diseases: From Molecular Mechanisms to Clinical Applications. *Oxidative medicine and cellular longevity* **2017**, 2017, 2525967-2525967.

43. Mouzat, K.; Chudinova, A.; Polge, A.; Kantar, J.; Camu, W.; Raoul, C.; Lumbruso, S., Regulation of Brain Cholesterol: What Role Do Liver X Receptors Play in Neurodegenerative Diseases? *Int J Mol Sci* **2019**, 20, (16), 3858.
44. Ito, A.; Hong, C.; Rong, X.; Zhu, X.; Tarling, E. J.; Hedde, P. N.; Gratton, E.; Parks, J.; Tontonoz, P., LXR agonists link metabolism to inflammation through Abca1-dependent regulation of membrane composition and TLR signaling. *eLife* 2015, 4, e08009.

45. Xu, P.; Li, D.; Tang, X.; Bao, X.; Huang, J.; Tang, Y.; Yang, Y.; Xu, H.; Fan, X., LXR agonists: new potential therapeutic drug for neurodegenerative diseases. *Molecular neurobiology* 2013, 48, (3), 715-28.

46. Dai, Y. B.; Tan, X. J.; Wu, W. F.; Warner, M.; Gustafsson, J. A., Liver X receptor beta protects dopaminergic neurons in a mouse model of Parkinson disease. *Proceedings of the National Academy of Sciences of the United States of America* 2012, 109, (32), 13112-7.

47. Futter, M.; Diekmann, H.; Schoenmakers, E.; Sadiq, O.; Chatterjee, K.; Rubinsztein, D. C., Wild-type but not mutant huntingtin modulates the transcriptional activity of liver X receptors. *Journal of medical genetics* 2009, 46, (7), 438-46.

48. Wolf, A.; Bauer, B.; Hartz, A. M., ABC Transporters and the Alzheimer's Disease Enigma. *Frontiers in psychiatry* 2012, 3, 54.

49. Campbell, B. C. V.; De Silva, D. A.; Macleod, M. R.; Coutts, S. B.; Schwamm, L. H.; Davis, S. M.; Donnan, G. A., Ischaemic stroke. *Nature Reviews Disease Primers* 2019, 5, (1), 70.

50. Soares, R. O. S.; Losada, D. M.; Jordan, M. C.; Évora, P.; Castro-E-Silva, O., Ischemia/Reperfusion Injury Revisited: An Overview of the Latest Pharmacological Strategies. *Int J Mol Sci* 2019, 20, (20), 5034.

51. Wu, L.; Xiong, X.; Wu, X.; Ye, Y.; Jian, Z.; Zhi, Z.; Gu, L., Targeting Oxidative Stress and Inflammation to Prevent Ischemia-Reperfusion Injury. In *Frontiers in molecular neuroscience*, 2020; Vol. 13, p 28.

52. Tschoe, C.; Bushnell, C. D.; Duncan, P. W.; Alexander-Miller, M. A.; Wolfe, S. Q., Neuroinflammation after Intracerebral Hemorrhage and Potential Therapeutic Targets. *Journal of stroke* 2020, 22, (1), 29-46.

53. Liu, F.; Lu, J.; Manaenko, A.; Tang, J.; Hu, Q., Mitochondria in Ischemic Stroke: New Insight and Implications. *Aging and disease* 2018, 9, (5), 924-937.

54. Yang, J. L.; Mukda, S.; Chen, S. D., Diverse roles of mitochondria in ischemic stroke. *Redox biology* 2018, 16, 263-275.

55. Gadani, S. P.; Walsh, J. T.; Lukens, J. R.; Kipnis, J., Dealing with Danger in the CNS: The Response of the Immune System to Injury. *Neuron* 2015, 87, (1), 47-62.

56. Mracsko, E.; Veltkamp, R., Neuroinflammation after intracerebral hemorrhage. *Frontiers in cellular neuroscience* 2014, 8, 388.

57. Malekahmadi, M.; Moradi Moghaddam, O.; Islam, S. M. S.; Tanha, K.; Nematy, M.; Pahlavani, N.; Firouzi, S.; Zali, M. R.; Norouzy, A., Evaluation of the effects of pycnogenol (French maritime pine bark extract) supplementation on inflammatory biomarkers and nutritional and clinical status in traumatic brain injury patients in an intensive care unit: A randomized clinical trial protocol. *Trials* 2020, 21, (1), 162.

58. Beauchamp, K.; Matlak, H.; Smith, W. R.; Shoahmi, E.; Stahel, P. F. J. M. M., Pharmacology of traumatic brain injury: where is the “golden bullet”? *2008*, 14, (11), 731-740.

59. Khatri, N.; Thakur, M.; Pareek, V.; Kumar, S.; Sharma, S.; Datusalia, A. K. J. C.; Targets, N. D.-
60. Rodriguez-Rodriguez, A.; Jose Egea-Guerrero, J.; Murillo-Cabezas, F.; Carrillo-Vico, A. J. C. m. c., Oxidative stress in traumatic brain injury. 2018, 17, (9), 689-695.

61. Heo, S.-J.; Ko, S.-C.; Kang, S.-M.; Kang, H.-S.; Kim, J.-P.; Kim, S.-H.; Lee, K.-W.; Cho, M.-G.; Jeon, Y.-J., Cytoprotective effect of fucoxanthin isolated from brown alga Sargassum siliquastrum against H2O2-induced cell damage. European Food Research and Technology 2008, 228, (1), 145-151.

62. Zhao, D.; Kwon, S.-H.; Chun, Y. S.; Gu, M.-Y.; Yang, H. O., Anti-Neuroinflammatory Effects of Fucoxanthin via Inhibition of Akt/NF-κB and MAPKs/AP-1 Pathways and Activation of PKA/CREB Pathway in Lipopolysaccharide-Activated BV-2 Microglial Cells. Neurochem Res 2017, 42, (2), 667-677.

63. Lee, S.; Lee, Y. S.; Jung, S. H.; Kang, S. S.; Shin, K. H., Anti-oxidant activities of fucosterol from the marine algae Pelvetia siliquosa. Archives of pharmacal research 2003, 26, (9), 719-22.

64. Jung, H. A.; Jin, S. E.; Ahn, B. R.; Lee, C. M.; Choi, J. S., Anti-inflammatory activity of edible brown alga Eisenia bicyclis and its constituents fucosterol and phlorotannins in LPS-stimulated RAW264.7 macrophages. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 2013, 59, 199-206.

65. Choi, J. S.; Han, Y. R.; Byeon, J. S.; Choung, S. Y.; Sohn, H. S.; Jung, H. A., Protective effect of fucosterol isolated from the edible brown alga, Ecklonia stolonifera and Eisenia bicyclis, on tert-butyl hydroperoxide- and tacrine-induced HepG2 cell injury. The Journal of pharmacy and pharmacology 2015, 67, (8), 1170-8.

66. Fernando, I. P. S.; Jayawardena, T. U.; Kim, H.-S.; Lee, W. W.; Vaas, A. P. J. P.; De Silva, H. I. C.; Abayaweera, G. S.; Nanayakkara, C. M.; Abeytunga, D. T. U.; Lee, D.-S.; Jeon, Y.-J., Beijing urban particulate matter-induced injury and inflammation in human lung epithelial cells and the protective effects of fucosterol from Sargassum binderi (Sonder ex J. Agardh). Environmental Research 2019, 172, 150-158.

67. Rafiquzzaman, S. M.; Kim, E. Y.; Lee, J. M.; Mohibbullah, M.; Alam, M. B.; Soo Moon, I.; Kim, J.-M.; Kong, I.-S., Anti-Alzheimers and anti-inflammatory activities of a glycoprotein purified from the edible brown alga Undaria pinnatifida. Food Research International 2015, 77, 118-124.

68. Zou, Y.; Qian, Z.-J.; Li, Y.; Kim, M.-M.; Lee, S.-H.; Kim, S.-K., Antioxidant Effects of Phlorotannins Isolated from Ishige okamurae in Free Radical Mediated Oxidative Systems. Journal of Agricultural and Food Chemistry 2008, 56, (16), 7001-7009.

69. Zhang, Q.; Yu, P.; Li, Z.; Zhang, H.; Xu, Z.; Li, P., Antioxidant activities of sulfated polysaccharide fractions from Porphyra haitanesis. Journal of Applied Phycology 2003, 15, (4), 305-310.

70. Isaka, S.; Cho, K.; Nakazono, S.; Abu, R.; Ueno, M.; Kim, D.; Oda, T., Antioxidant and anti-inflammatory activities of porphyran isolated from discolored nori (Porphyra yezoensis). Int J Biol Macromol 2015, 74, 68-75.
71. Anggadiredja, J.; Andyani, R.; Hayati; Muawanah, Antioxidant activity of Sargassum polycystum (Phaeophyta) and Laurencia obtusa (Rhodophyta) from Seribu Islands. *Journal of Applied Phycology* 1997, 9, (5), 477.

72. Rengasamy, K. R. R.; Amoo, S. O.; Aremu, A. O.; Stirk, W. A.; Gruz, J.; Šubrtová, M.; Doležal, K.; Van Staden, J., Phenolic profiles, antioxidant capacity, and acetylcholinesterase inhibitory activity of eight South African seaweeds. *Journal of Applied Phycology* 2015, 27, (4), 1599-1605.

73. Hannan, M. A.; Sohag, A. A. M.; Dash, R.; Haque, M. N.; Mohibbullah, M.; Oktaviani, D. F.; Hossain, M. T.; Choi, H. J.; Moon, I. S., Phytoestrogens of marine algae: Insights into the potential health benefits and molecular pharmacology. *Phytomedicine* 2020, 69, 153201.

74. Sun, Z.; Mohamed, M. A. A.; Park, S. Y.; Yi, T. H., Fucosterol protects cobalt chloride induced inflammation by the inhibition of hypoxia-inducible factor through PI3K/Akt pathway. *Int Immunopharmacol* 2015, 29, (2), 642-647.

75. Yoo, M. S.; Shin, J. S.; Choi, H. E.; Cho, Y. W.; Bang, M. H.; Baek, N. I.; Lee, K. T., Fucosterol isolated from Undaria pinnatifida inhibits lipopolysaccharide-induced production of nitric oxide and pro-inflammatory cytokines via the inactivation of nuclear factor kappaB and p38 mitogen-activated protein kinase in RAW264.7 macrophages. *Food chemistry* 2012, 135, (3), 967-75.

76. Brandhorst, S.; Choi, I. Y.; Wei, M.; Cheng, C. W.; Sedrakyan, S.; Navarrete, G.; Dubeau, L.; Yap, L. P.; Park, R.; Vinciguerra, M.; Di Biase, S.; Mirzaei, H.; Mirisola, M. G.; Childress, P.; Ji, L.; Groshen, S.; Penna, F.; Odetti, P.; Perin, L.; Conti, P. S.; Ikeno, Y.; Kennedy, B. K.; Cohen, P.; Morgan, T. E.; Dorff, T. B.; Longo, V. D., A Periodic Diet that Mimics Fasting Promotes Multi-System Regeneration, Enhanced Cognitive Performance, and Healthspan. *Cell Metab* 2015, 22, (1), 86-99.

77. Wong, C. H.; Gan, S. Y.; Tan, S. C.; Gany, S. A.; Ying, T.; Gray, A. I.; Igoli, J.; Chan, E. W. L.; Phang, S. M., Fucosterol inhibits the cholinesterase activities and reduces the release of pro-inflammatory mediators in lipopolysaccharide and amyloid-induced microglial cells. *Journal of applied phycology* 2018, 30, (6), 3261-3270.

78. Jung, W.-K.; Heo, S.-J.; Jeon, Y.-J.; Lee, C.-M.; Park, Y.-M.; Byun, H.-G.; Choi, Y. H.; Park, S.-G.; Choi, I.-W., Inhibitory effects and molecular mechanism of dieckol isolated from marine brown alga on COX-2 and iNOS in microglial cells. *Journal of agricultural and food chemistry* 2009, 57, (10), 4439-4446.

79. Kim, A. R.; Lee, M.-S.; Choi, J.-W.; Utsuki, T.; Kim, J.-I.; Jang, B.-C.; Kim, H.-R., Phlorofucofuroeckol A suppresses expression of inducible nitric oxide synthase, cyclooxygenase-2, and pro-inflammatory cytokines via inhibition of nuclear factor-κB, c-Jun NH2-terminal kinases, and Akt in microglial cells. *Inflammation* 2013, 36, (2), 259-271.

80. Yu, D.-K.; Lee, B.; Kwon, M.; Yoon, N.; Shin, T.; Kim, N.-G.; Choi, J.-S.; Kim, H.-R., Phlorofucofuroeckol B suppresses inflammatory responses by down-regulating nuclear factor κB activation via Akt, ERK, and JNK in LPS-stimulated microglial cells. *Int Immunopharmacol* 2015, 28, (2), 1068-1075.

81. Kim, A. R.; Lee, B.; Joung, E.-J.; Gwon, W.-G.; Utsuki, T.; Kim, N.-G.; Kim, H.-R., 6,6’-Bieckol
suppresses inflammatory responses by down-regulating nuclear factor-κB activation via Akt, JNK, and p38 MAPK in LPS-stimulated microglial cells. *Immunopharmacol Immunotoxicol* 2016, 38, (3), 244-252.

82. Yang, Y.-I.; Jung, S.-H.; Lee, K.-T.; Choi, J.-H., 8,8'-Bieckol, isolated from edible brown algae, exerts its anti-inflammatory effects through inhibition of NF-κB signaling and ROS production in LPS-stimulated macrophages. *Int Immunopharmacol* 2014, 23, (2), 460-468.

83. Park, H. Y.; Han, M. H.; Park, C.; Jin, C.-Y.; Kim, G.-Y.; Choi, I.-W.; Kim, N. D.; Nam, T.-J.; Kwon, T. K.; Choi, Y. H., Anti-inflammatory effects of fucoidan through inhibition of NF-κB, MAPK and Akt activation in lipopolysaccharide-induced BV2 microglia cells. *Food Chem Toxicol* 2011, 49, (8), 1745-1752.

84. Cui, Y.-Q.; Jia, Y.-J.; Zhang, T.; Zhang, Q.-B.; Wang, X.-M., Fucoidan Protects against Lipopolysaccharide-Induced Rat Neuronal Damage and Inhibits the Production of Proinflammatory Mediators in Primary Microglia. *CNS Neurosci Ther* 2012, 18, (10), 827-833.

85. Yao, Z.-A.; Xu, L.; Wu, H.-G., Immunomodulatory function of κ-carrageenan oligosaccharides acting on LPS-activated microglial cells. *Neurochem Res* 2014, 39, (2), 333-343.

86. Jiang, Z.; Hama, Y.; Yamaguchi, K.; Oda, T., Inhibitory effect of sulphated polysaccharide porphyran on nitric oxide production in lipopolysaccharide-stimulated RAW264.7 macrophages. *Journal of biochemistry* 2012, 151, (1), 65-74.

87. Liu, X.-Y.; Liu, D.; Lin, G.-P.; Wu, Y.-J.; Gao, L.-Y.; Ai, C.; Huang, Y.-F.; Wang, M.-F.; El-Seedi, H. R.; Chen, X.-H.; Zhao, C., Anti-ageing and antioxidant effects of sulfate oligosaccharides from green algae Ulva lactuca and Enteromorpha prolifera in SAMP8 mice. *Int J Biol Macromol* 2019, 139, 342-351.

88. Zhou, R.; Shi, X.-Y.; Bi, D.-C.; Fang, W.-S.; Wei, G.-B.; Xu, X., Alginate-Derived Oligosaccharide Inhibits Neuroinflammation and Promotes Microglial Phagocytosis of β-Amyloid. *Mar Drugs* 2015, 13, (9), 5828-5846.

89. Bi, D.; Lai, Q.; Han, Q.; Cai, N.; He, H.; Fang, W.; Yi, J.; Li, X.; Xu, H.; Li, X.; Hu, Z.; Liu, Q.; Xu, X., Seleno-polymannuronate attenuates neuroinflammation by suppressing microglial and astrocytic activation. *Journal of Functional Foods* 2018, 51, 113-120.

90. Yang, E. J.; Ham, Y. M.; Yang, K. W.; Lee, N. H.; Hyun, C. G., Sargachromenol from Sargassum micracanthum inhibits the lipopolysaccharide-induced production of inflammatory mediators in RAW 264.7 macrophages. *TheScientificWorldJournal* 2013, 2013, 712303.

91. Kang, G. J.; Han, S. C.; Yoon, W. J.; Koh, Y. S.; Hyun, J. W.; Kang, H. K.; Youl Cho, J.; Yoo, E. S., Sargaquinoic acid isolated from Sargassum silquastrum inhibits lipopolysaccharide-induced nitric oxide production in macrophages via modulation of nuclear factor-kB and c-Jun N-terminal kinase pathways. *Immunopharmacol Immunotoxicol* 2013, 35, (1), 80-7.

92. Kim, M.; Li, Y.-X.; Dewapriya, P.; Ryu, B.; Kim, S.-K., Floridoside suppresses pro-inflammatory responses by blocking MAPK signaling in activated microglia. *BMB Rep* 2013, 46, (8), 398-403.

93. de Souza, E. T.; de Lira, D. P.; de Queiroz, A. C.; da Silva, D. J. C.; de Aquino, A. B.; Mella, E.
94. Cengiz, S.; Cavas, L.; Yurdakoc, K.; Pohnert, G., The Sesquiterpene Caulerpenyne from Caulerpa spp. is a Lipoxygenase Inhibitor. *Marine Biotechnology* 2011, 13, (2), 321-326.

95. Ryan, S.; O’Gorman, D. M.; Nolan, Y. M., Evidence that the marine-derived multi-mineral Aquamin has anti-inflammatory effects on cortical glial-enriched cultures. *Phytother Res* 2011, 25, (5), 765-7.

96. Yoon, N. Y.; Chung, H. Y.; Kim, H. R.; Choi, J. S., Acetyl- and butyrylcholinesterase inhibitory activities of sterols and phlorotannins from Ecklonia stolonifera. *Fisheries Science* 2008, 74, (1), 200-207.

97. Castro-Silva, E. S.; Bello, M.; Hernandez-Rodriguez, M.; Correa-Basurto, J; Murillo-Alvarez, J. I.; Rosales-Hernandez, M. C.; Munoz-Ochoa, M., In vitro and in silico evaluation of fucosterol from Sargassum horridum as potential human acetylcholinesterase inhibitor. *Journal of biomolecular structure & dynamics* 2019, 37, (12), 3259-3268.

98. Kawee-ai, A.; Kuntiya, A.; Kim, S. M., Anticholinesterase and antioxidant activities of fucoxanthin purified from the microalgae Phaeodactylum tricornutum. *Nat Prod Commun* 2013, 8, (10), 1381-1386.

99. Lin, J.; Huang, L.; Yu, J.; Xiang, S.; Wang, J.; Zhang, J.; Yan, X.; Cui, W.; He, S.; Wang, Q., Fucoxanthin, a Marine Carotenoid, Reverses Scopolamine-Induced Cognitive Impairments in Mice and Inhibits Acetylcholinesterase in Vitro. *Mar Drugs* 2016, 14, (4), 67.

100. Shanmuganathan, B.; Sheeja Malar, D.; Sathya, S.; Pandima Devi, K., Antiaggregation Potential of Padina gymnospora against the Toxic Alzheimer’s Beta-Amyloid Peptide 25-35 and Cholinesterase Inhibitory Property of Its Bioactive Compounds. *PLoS One* 2015, 10, (11), e0141708-e0141708.

101. Kannan, R. R. R.; Aderogba, M. A.; Ndhlala, A. R.; Stirk, W. A.; Van Staden, J., Acetylcholinesterase inhibitory activity of phlorotannins isolated from the brown alga, Ecklonia maxima (Osbeck) Papenfuss. *Food Research International* 2013, 54, (1), 1250-1254.

102. Myung, C.-S.; Shin, H.-C.; Bao, H. Y.; Yeo, S. J.; Lee, B. H.; Kang, J. S., Improvement of memory by dieckol and phlorofucofuroeckol in ethanol-treated mice: possible involvement of the inhibition of acetylcholinesterase. *Arch Pharm Res* 2005, 28, (6), 691-698.

103. Choi, B. W.; Ryu, G.; Park, S. H.; Kim, E. S.; Shin, J.; Roh, S. S.; Shin, H. C.; Lee, B. H., Anticholinesterase activity of plastoquinones from Sargassum sagamianum: lead compounds for Alzheimer’s disease therapy. *Phytother Res* 2007, 21, (5), 423-426.

104. Ryu, G.; Park, S. H.; Kim, E. S.; Choi, B. W.; Ryu, S. Y.; Lee, B. H., Cholinesterase inhibitory activity of two farnesylacetone derivatives from the brown alga Sargassum sagamianum. *Arch Pharm Res* 2003, 26, (10), 796-799.

105. Jung, H. A.; Ali, M. Y.; Choi, R. J.; Jeong, H. O.; Chung, H. Y.; Choi, J. S., Kinetics and molecular docking studies of fucosterol and fucoxanthin, BACE1 inhibitors from brown algae Undaria
pinnatifida and Ecklonia stolonifera. *Food and Chemical Toxicology* **2016**, *89*, 104-111.

106. Xiang, S.; Liu, F.; Lin, J.; Chen, H.; Huang, C.; Chen, L.; Zhou, Y.; Ye, L.; Zhang, K.; Jin, J.; Zhen, J.; Wang, C.; He, S.; Wang, Q.; Cui, W.; Zhang, J., Fucoxanthin Inhibits β-Amyloid Assembly and Attenuates β-Amyloid Oligomer-Induced Cognitive Impairments. *Journal of agricultural and food chemistry* **2017**, *65*, (20), 4092-4102.

107. Alghazwi, M.; Smid, S.; Musgrave, I.; Zhang, W., In vitro studies of the neuroprotective activities of astaxanthin and fucoxanthin against amyloid beta (Aβ(1-42)) toxicity and aggregation. *Neurochem Int* **2019**, *124*, 215-224.

108. Shanmuganathan, B.; Suryanarayanan, V.; Sathy, S.; Narenkumar, M.; Singh, S. K.; Ruckmani, K.; Pandima Devi, K., Anti-amyloidogenic and anti-apoptotic effect of α-bisabolol against Aβ induced neurotoxicity in PC12 cells. *Eur J Med Chem* **2018**, *143*, 1196-1207.

109. Hoang, M.-H.; Jia, Y.; Jun, H.-j.; Lee, J. H.; Lee, B. Y.; Lee, S.-J., Fucosterol Is a Selective Liver X Receptor Modulator That Regulates the Expression of Key Genes in Cholesterol Homeostasis in Macrophages, Hepatocytes, and Intestinal Cells. *Journal of agricultural and food chemistry* **2012**, *60*, (46), 11567-11575.

110. Chen, Z.; Liu, J.; Fu, Z.; Ye, C.; Zhang, R.; Song, Y.; Zhang, Y.; Li, H.; Ying, H.; Liu, H., 24(S)-Saringosterol from edible marine seaweed Sargassum fusiforme is a novel selective LXRβ agonist. *Journal of agricultural and food chemistry* **2014**, *62*, (26), 6130-7.

111. Seong, S. H.; Paudel, P.; Choi, J.-W.; Ahn, D. H.; Nam, T.-J.; Jung, H. A.; Choi, J. S., Probing Multi-Target Action of Phlorotannins as New Monoamine Oxidase Inhibitors and Dopaminergic Receptor Modulators with the Potential for Treatment of Neuronal Disorders. *Mar Drugs* **2019**, *17*, (6), 377.

112. Oktaviani, D. F.; Bae, Y.-S.; Meinita, M. D. N.; Moon, I. S.; Hong, Y.-K., An Ethanol Extract of the Brown Seaweed Hizikia fusiformis and Its Active Constituent, Fucosterol, Extend the Lifespan of the Nematode Caenorhabditis elegans. *Journal of Life Science* **2019**, *29*, (10), 1120-1125.

113. Souza, C. R. M.; Bezerra, W. P.; Souto, J. T., Marine Alkaloids with Anti-Inflammatory Activity: Current Knowledge and Future Perspectives. *Mar Drugs* **2020**, *18*, (3).

114. Jung, W.-K.; Ahn, Y.-W.; Lee, S.-H.; Choi, Y. H.; Kim, S.-K.; Yea, S. S.; Choi, I.; Park, S.-G.; Seo, S.-K.; Lee, S.-W.; Choi, I.-W., Ecklonia cava ethanolic extracts inhibit lipopolysaccharide-induced cyclooxygenase-2 and inducible nitric oxide synthase expression in BV2 microglia via the MAP kinase and NF-kappaB pathways. *Food Chem Toxicol* **2009**, *47*, (2), 410-417.

115. Kim, S.; Kim, J.-I.; Choi, J.-W.; Kim, M.; Yoon, N. Y.; Choi, C.-G.; Choi, J.-S.; Kim, H.-R., Anti-inflammatory effect of hexane fraction from Myagropsis myagroides ethanolic extract in lipopolysaccharide-stimulated BV-2 microglial cells. *J Pharm Pharmacol* **2013**, *65*, (6), 895-906.

116. Kim, S.; Lee, M.-S.; Lee, B.; Gwon, W.-G.; Joung, E.-J.; Yoon, N.-Y.; Kim, H.-R., Anti-inflammatory effects of sargachromenol-rich ethanolic extract of Myagropsis myagroides on lipopolysaccharide-stimulated BV-2 cells. *BMC Complement Altern Med* **2014**, *14*, 231-231.
117. Oh, S.-J.; Joung, E.-J.; Kwon, M.-S.; Lee, B.; Utsuki, T.; Oh, C.-W.; Kim, H.-R., Anti-Inflammatory Effect of Ethanolic Extract of Sargassum serratifolium in Lipopolysaccharide-Stimulated BV2 Microglial Cells. J Med Food 2016, 19, (11), 1023-1031.

118. Gany, S. A.; Tan, S. C.; Gan, S. Y., Antioxidative, anticholinesterase and anti-neuroinflammatory properties of Malaysian brown and green seaweeds. World Acad Sci Eng Technol 2015, 8, 1269-75.

119. Jin, D.-Q.; Lim, C. S.; Sung, J.-Y.; Choi, H. G.; Ha, I.; Han, J.-S., Ulva conglobata, a marine algae, has neuroprotective and anti-inflammatory effects in murine hippocampal and microglial cells. Neurosci Lett 2006, 402, (1-2), 154-158.

120. Gwon, W.-G.; Lee, M.-S.; Kim, J.-S.; Kim, J.-I.; Lim, C.-W.; Kim, N.-G.; Kim, H.-R., Hexane fraction from Sargassum fulvellum inhibits lipopolysaccharide-induced inducible nitric oxide synthase expression in RAW 264.7 cells via NF-κB pathways. Am J Chin Med 2013, 41, (3), 565-584.

121. Kim, M. E.; Jung, Y. C.; Jung, I.; Lee, H.-W.; Youn, H.-Y.; Lee, J. S., Anti-inflammatory effects of ethanolic extract from Sargassum horneri (Turner C. Agardh) on lipopolysaccharide-stimulated macrophage activation via NF-κB pathway regulation. Immunol Invest 2015, 44, (2), 137-146.

122. Joung, E.-J.; Lee, M.-S.; Choi, J.-W.; Kim, J.-S.; Shin, T.; Jung, B.-M.; Yoon, N. Y.; Lim, C.-W.; Kim, J.-I.; Kim, H.-R., Anti-inflammatory effect of ethanolic extract from Myagropsis myagroides on murine macrophages and mouse ear edema. BMC Complement Altern Med 2012, 12, 171-171.

123. Joung, E.-J.; Lee, M.-S.; Choi, J.-W.; Kim, J.-S.; Shin, T.; Jung, B.-M.; Kim, J.-I.; Kim, H.-R., Anti-inflammatory effects of phlorofucofuroeckol B-rich ethyl acetate fraction obtained from Myagropsis myagroides on lipopolysaccharide-stimulated RAW 264.7 cells and mouse edema. Int Immunopharmacol 2012, 14, (4), 471-480.

124. Joung, E.-J.; Gwon, W.-G.; Shin, T.; Jung, B.-M.; Choi, J.; Kim, H.-R., Anti-inflammatory action of the ethanolic extract from Sargassum serratifolium on lipopolysaccharide-stimulated mouse peritoneal macrophages and identification of active components. Journal of Applied Phycology 2017, 29, (1), 563-573.

125. Rengasamy, K. R. R.; Aderogba, M. A.; Amoo, S. O.; Stirk, W. A.; Van Staden, J., Macrocystis angustifolia is a potential source of enzyme inhibitors linked to type 2 diabetes and dementia. Journal of Applied Phycology 2014, 26, (3), 1557-1563.

126. Seong, S. H.; Ali, M. Y.; Kim, H. R.; Jung, H. A.; Choi, J. S., BACE1 inhibitory activity and molecular docking analysis of meroterpenoids from Sargassum serratifolium. Bioorganic & medicinal chemistry 2017, 25, (15), 3964-3970.

127. Lee, J.; Jun, M., Dual BACE1 and Cholinesterase Inhibitory Effects of Phlorotannins from Ecklonia cava-An In Vitro and in Silico Study. Mar Drugs 2019, 17, (2).

128. Custódio, L.; Soares, F.; Pereira, H.; Rodrigues, M. J.; Barreira, L.; Rauter, A. P.; Albericio, F.; Varela, J., Botryococcus braunii and Nannochloropsis oculata extracts inhibit cholinesterases and protect human dopaminergic SH-SY5Y cells from H2O2-induced cytotoxicity. Journal of Applied Phycology 2015, 27, (2), 839-848.
129. Custódio, L.; Silvestre, L.; Rocha, M. I.; Rodrigues, M. J.; Vizetto-Duarte, C.; Pereira, H.; Barreira, L.; Varela, J., Methanol extracts from Cystoseira tamariscifolia and Cystoseira nodicaulis are able to inhibit cholinesterases and protect a human dopaminergic cell line from hydrogen peroxide-induced cytotoxicity. *Pharm Biol* 2016, 54, (9), 1687-96.

130. Kim, T.-E.; Son, H. J.; Lim, D. W.; Yoon, M.; Lee, J.; Kim, Y. T.; Han, D.; Lee, C.; Um, M. Y., Memory-enhancing effects of Ishige foliacea extract: In vitro and in vivo study. *Journal of Food Biochemistry* 2020, 44, (4), e13162.

131. Nunes, N.; Rosa, G. P.; Ferraz, S.; Barreto, M. C.; de Carvalho, M. A. A. P., Fatty acid composition, TLC screening, ATR-FTIR analysis, anti-cholinesterase activity, and in vitro cytotoxicity to A549 tumor cell line of extracts of 3 macroalgae collected in Madeira. *Journal of Applied Phycology* 2019.

132. Hannan, M. A.; Dash, R.; Sohag, A. A. M.; Moon, I. S., Deciphering Molecular Mechanism of the Neuropharmacological Action of Fucosterol through Integrated System Pharmacology and In Silico Analysis. *Marine Drugs* 2019, 17, (11), 639.

133. Dezsi, L.; Vecsei, L., Monoamine Oxidase B Inhibitors in Parkinson's Disease. *CNS & neurological disorders drug targets* 2017, 16, (4), 425-439.

134. Abdul, Q. A.; Choi, R. J.; Jung, H. A.; Choi, J. S., Health benefit of fucosterol from marine algae: a review. *J Sci Food Agric* 2016, 96, (6), 1856-66.

135. Tsang, C. K.; Ina, A.; Goto, T.; Kamei, Y., Sargachromenol, a novel nerve growth factor-potentiating substance isolated from Sargassum macrocarpum, promotes neurite outgrowth and survival via distinct signaling pathways in PC12D cells. *Neuroscience* 2005, 132, (3), 633-643.

136. Ina, A.; Hayashi, K.-I.; Nozaki, H.; Kamei, Y., Pheophytin a, a low molecular weight compound found in the marine brown alga Sargassum fulvellum, promotes the differentiation of PC12 cells. *Int J Dev Neurosci* 2006, 52, (3), 181-7.

137. Mohibullah, M.; Choi, J.-S.; Bhuiyan, M. M. H.; Haque, M. N.; Rahman, M. K.; Moon, I. S.; Hong, Y.-K., The Red Alga Gracilaria chorda and Its Active Constituent Arachidonic Acid Promote Spine Dynamics via Dendritic Filopodia and Potentiate Functional Synaptic Plasticity in Hippocampal Neurons. *J Med Food* 2018, 21, (5), 481-488.

138. Kamei, Y.; Sagara, A., Neurite outgrowth promoting activity of marine algae from Japan against rat adrenal medulla pheochromocytoma cell line, PC12D. *Cytotechnology* 2002, 40, (1-3), 99-106.
13. Mohibbullah, M.; Bhuiyan, M. M.; Hannan, M. A.; Getachew, P.; Hong, Y. K.; Choi, J. S.; Choi, I. S.; Moon, I. S., The Edible Red Alga Porphyra yezoensis Promotes Neuronal Survival and Cytoarchitecture in Primary Hippocampal Neurons. *Cell Mol Neurobiol* 2016, 36, (5), 669-82.

14. Hannan, M. A.; Haque, M. N.; Mohibbullah, M.; Dash, R.; Hong, Y.-K.; Moon, I. S., Gelidium amansii Attenuates Hypoxia/Reoxygenation-Induced Oxidative Injury in Primary Hippocampal Neurons through Suppressing GluN2B Expression. *2020*, 9, (3), 223.

15. Hannan, M. A.; Mohibbullah, M.; Hong, Y.-K.; Moon, I. S., Proteomic Analysis of the Neurotrophic Effect of Gelidium amansii in Primary Cultured Neurons. *Journal of Medicinal Food* 2017, 20, (3), 279-287.

16. Hannan, M. A.; Mohibbullah, M.; Hong, Y.-K.; Nam, J. H.; Moon, I. S., Gelidium amansii promotes dendritic spine morphology and synaptogenesis, and modulates NMDA receptor-mediated postsynaptic current. *In Vitro Cellular & Developmental Biology - Animal* 2014, 50, (5), 445-452.

17. Hannan, M. A.; Kang, J. Y.; Tong, Y. K.; Lee, H.; Chowdhury, M. T.; Choi, J. S.; Choi, I. S.; Moon, I. S., A brown alga Sargassum fulvellum facilitates neuronal maturation and synaptogenesis. *In vitro cellular & developmental biology. Animal* 2012, 48, (8), 535-44.

18. Hannan, M. A.; Mohibbullah, M.; Hwang, S.-Y.; Lee, K.; Kim, Y.-C.; Hong, Y.-K.; Moon, I. S., Differential neuritogenic activities of two edible brown macroalgae, Undaria pinnatifida and Saccharina japonica. *The American journal of Chinese medicine* 2014, 42, (06), 1371-1384.

19. Mohibbullah, M.; Hannan, M. A.; Park, I.-S.; Moon, I. S.; Hong, Y.-K.; The Edible Red Seaweed Gracilariopsis chorda Promotes Axodendritic Architectural Complexity in Hippocampal Neurons. *Journal of Medicinal Food* 2016, 19, (7), 638-644.

20. Tirtawijaya, G.; Mohibbullah, M.; Meinita, M. D. N.; Moon, I. S.; Hong, Y.-K., The tropical carrageenophyte Kappaphycus alvarezii extract promotes axodendritic maturation of hippocampal neurons in primary culture. *Journal of Applied Phycology* 2018, 30, (6), 3233-3241.

21. Tirtawijaya, G.; Mohibbullah, M.; Meinita, M. D. N.; Moon, I. S.; Hong, Y.-K., The ethanol extract of the rhodophyte Kappaphycus alvarezii promotes neurite outgrowth in hippocampal neurons. *Journal of Applied Phycology* 2016, 28, (4), 2515-2522.

22. Tirtawijaya, G.; Haque, M. N.; Choi, J. S.; Moon, I. S.; Meinita, M. D. N.; Choi, J.-S.; Hong, Y.-K. J. P. N.; Science, F., Spino genesis and Synaptogenesis Effects of the Red Seaweed Kappaphycus alvarezii and Its Isolated Cholesterol on Hippocampal Neuron Cultures. 2019, 24, (4), 418.

23. Tirtawijaya, G.; Meinita, M. D. N.; Marhaeni, B.; Haque, M. N.; Moon, I. S.; Hong, Y.-K., Neurotrophic Activity of the Carrageenophyte Kappaphycus alvarezii Cultivated at Different Depths and for Different Growth Periods in Various Areas of Indonesia. *Evidence-
154. Lin, J.; Yu, J.; Zhao, J.; Zhang, K.; Zheng, J.; Wang, J.; Huang, C.; Zhang, J.; Yan, X.; Gerwick, W. H.; Wang, Q.; Cui, W.; He, S., Fucoxanthin, a Marine Carotenoid, Attenuates β-Amyloid Oligomer-Induced Neurotoxicity Possibly via Regulating the PI3K/Akt and the ERK Pathways in SH-SYSY Cells. *Oxid Med Cell Longev* 2017, 6792543-6792543.

155. Yu, J.; Lin, J.-J.; Yu, R.; He, S.; Wang, Q.-W.; Cui, W.; Zhang, J.-R., Fucoxanthin prevents H(2)O(2)-induced neuronal apoptosis via concurrently activating the PI3-K/Akt cascade and inhibiting the ERK pathway. *Food Nutr Res* 2017, 61, (1), 1304678-1304678.

156. Ikeda, K.; Kitamura, A.; Machida, H.; Watanabe, M.; Negishi, H.; Hiraoka, J.; Nakano, T., Effect of Undaria pinnatifida (Wakame) on the development of cerebrovascular diseases in stroke-prone spontaneously hypertensive rats. *Clin Exp Pharmacol Physiol* 2003, 30, (1-2), 44-48.

157. Mohibullah, M.; Haque, M. N.; Khan, M. N. A.; Park, I.-S.; Moon, I. S.; Hong, Y.-K., Neuroprotective effects of fucoxanthin and its derivative fucoxanthinol from the phaeophyte Undaria pinnatifida attenuate oxidative stress in hippocampal neurons. *Journal of Applied Phycology* 2018, 30, (6), 3243-3252.

158. Hu, L.; Chen, W.; Tian, F.; Yuan, C.; Wang, H.; Yue, H., Neuroprotective role of fucoxanthin against cerebral ischemic/reperfusion injury through activation of Nrf2/HO-1 signaling. *Biomed Pharmacother* 2018, 106, 1484-1489.

159. Zhang, L.; Wang, H.; Fan, Y.; Gao, Y.; Li, X.; Hu, Z.; Ding, K.; Wang, Y.; Wang, X., Fucoxanthin provides neuroprotection in models of traumatic brain injury via the Nrf2-ARE and Nrf2-autophagy pathways. *Sci Rep* 2017, 7, 46763-46763.

160. Shimizu, H.; Koyama, T.; Yamada, S.; Lipton, S. A.; Satoh, T., Zonarol, a sesquiterpene from the brown algae Dictyopteris undulata, provides neuroprotection by activating the Nrf2/ARE pathway. *Biochem Biophys Res Commun* 2015, 457, (4), 718-722.

161. Shanmuganathan, B.; Sathyya, S.; Balasubramaniam, B.; Balamurugan, K.; Devi, K. P., Amyloid-β induced neuropathological actions are suppressed by Padina gymnospora (Phaeophyceae) and its active constituent α-bisabolol in Neuro2a cells and transgenic Caenorhabditis elegans Alzheimers model. *Nitric Oxide* 2019, 91, 52-66.

162. Oh, J. H.; Choi, J. S.; Nam, T. J., Fucosterol from an Edible Brown Alga Ecklonia stolonifera Prevents Soluble Amyloid Beta-Induced Cognitive Dysfunction in Aging Rats. *Mar Drugs* 2018, 16, (10).

163. Gan, S. Y.; Wong, L. Z.; Wong, J. W.; Tan, E. L., Fucosterol exerts protection against amyloid β-induced neurotoxicity, reduces intracellular levels of amyloid β and enhances the mRNA expression of neuroglobin in amyloid β-induced SH-SYSY cells. *International journal of biological macromolecules* 2019, 121, 207-213.

164. Ahn, B. R.; Moon, H. E.; Kim, H. R.; Jung, H. A.; Choi, J. S., Neuroprotective effect of edible brown alga Eisenia bicyclis on amyloid beta peptide-induced toxicity in PC12 cells. *Arch Pharm Res* 2012, 35, (11), 1989-1998.

165. Yang, E.-J.; Ahn, S.; Ryu, J.; Choi, M.-S.; Choi, S.; Chong, Y. H.; Hyun, J.-W.; Chang, M.-J.; Kim, H.-S., Phloroglucinol Attenuates the Cognitive Deficits of the 5XFAD Mouse Model of
15. Alzheimer's Disease. *PLoS One* **2015**, 10, (8), e0135686-e0135686.

166. Kang, S.-M.; Cha, S.-H.; Ko, J.-Y; Kang, M.-C.; Kim, D.; Heo, S.-J.; Kim, J.-S.; Heu, M. S.; Kim, Y.-T.; Jung, W.-K.; Jeon, Y.-J., Neuroprotective effects of phlorotannins isolated from a brown alga, Ecklonia cava, against H2O2-induced oxidative stress in murine hippocampal HT22 cells. *Environ Toxicol Pharmacol* **2012**, 34, (1), 96-105.

167. Heo, S.-J.; Cha, S.-H.; Kim, K.-N.; Lee, S.-H.; Ahn, G.; Kang, D.-H.; Oh, C.; Choi, Y.-U.; Affan, A.; Kim, D.; Jeon, Y.-J., Neuroprotective effect of phlorotannin isolated from Ishige okamurae against H2O2-induced oxidative stress in murine hippocampal neuronal cells, HT22. *Appl Biochem Biotechnol* **2012**, 166, (6), 1520-1532.

168. Kim, J. J.; Kang, Y. J.; Shin, S. A.; Bak, D. H.; Lee, J. W.; Lee, K. B.; Yoo, Y. C.; Kim, D. K.; Lee, B. H.; Kim, D. W.; Lee, J.; Jo, E. K.; Yuk, J. M., Phlorofucofuroeckol Improves Glutamate-Induced Neurotoxicity through Modulation of Oxidative Stress-Mediated Mitochondrial Dysfunction in PC12 Cells. *PLoS One* **2016**, 11, (9), e0163433.

169. Wang, J.; Zheng, J.; Huang, C.; Zhao, J.; Lin, J.; Zhou, X.; Naman, C. B.; Wang, N.; Gerwick, W. H.; Wang, Q.; Yan, X.; Cui, W.; He, S., Eckmaxol, a Phlorotannin Extracted from Ecklonia maxima, Produces Anti-beta-amyloid Oligomer Neuroprotective Effects Possibly via Directly Acting on Glycogen Synthase Kinase 3beta. *ACS chemical neuroscience* **2018**, 9, (6), 1349-1356.

170. Jhamandas, J. H.; Wie, M. B.; Harris, K.; MacTavish, D.; Kar, S., Fucoidan inhibits cellular and neurotoxic effects of beta-amyloid (A beta) in rat cholinergic basal forebrain neurons. *Eur J Neurosci* **2005**, 21, (10), 2649-2659.

171. Luo, D.; Zhang, Q.; Wang, H.; Cui, Y.; Sun, Z.; Yang, J.; Zheng, Y.; Jia, J.; Yu, F.; Wang, X.; Wang, X., Fucoidan protects against dopaminergic neuron death in vivo and in vitro. *Eur J Pharmacol* **2009**, 617, (1-3), 33-40.

172. Gao, Y.; Dong, C.; Yin, J.; Shen, J.; Tian, J.; Li, C., Neuroprotective effect of fucoidan on H2O2-induced apoptosis in PC12 cells via activation of PI3K/Akt pathway. *Cell Mol Neurobiol* **2012**, 32, (4), 523-529.

173. Wei, H.; Gao, Z.; Zheng, L.; Zhang, C.; Liu, Z.; Yang, Y.; Teng, H.; Hou, L.; Yin, Y.; Zou, X., Protective Effects of Fucoidan on Aβ25-35 and d-Gal-Induced Neurotoxicity in PC12 Cells and d-Gal-Induced Cognitive Dysfunction in Mice. *Mar Drugs* **2017**, 15, (3).

174. Liang, Z.; Liu, Z.; Sun, X.; Tao, M.; Xiao, X.; Yu, G.; Wang, X., The Effect of Fucoidan on Cellular Oxidative Stress and the CatD-Bax Signaling Axis in MN9D Cells Damaged by 1-Methyl-4-Phenypyridinium. *Front Aging Neurosci* **2019**, 10, 429-429.

175. Wu, H.; Gao, S.; Terakawa, S., Inhibitory effects of fucoidan on NMDA receptors and L-type Ca(2+) channels regulating the Ca(2+) responses in rat neurons. *Pharm Biol* **2019**, 57, (1), 1-7.

176. Liu, Y.; Deng, Z.; Geng, L.; Wang, J.; Zhang, Q., In vitro evaluation of the neuroprotective effect of oligo-porphyrin from Porphyra yezoensis in PC12 cells. *Journal of Applied Phycology* **2019**, 31, (4), 2559-2571.

177. Wang, S.; Li, J.; Xia, W.; Geng, M., A marine-derived acidic oligosaccharide sugar chain specifically inhibits neuronal cell injury mediated by beta-amyloid-induced astrocyte
activation in vitro. *Neurological research* **2007**, 29, (1), 96-102.

178. Liu, D.-Q.; Mao, S.-C.; Zhang, H.-Y.; Yu, X.-Q.; Feng, M.-T.; Wang, B.; Feng, L.-H.; Guo, Y.-W., *Racemosins A and B*, two novel bisindole alkaloids from the green alga Caulerpa racemosa. *Fitoterapia* **2013**, 91, 15-20.

179. Wu, S.; Yue, Y.; Tian, H.; Tao, L.; Wang, Y.; Xiang, J.; Wang, S.; Ding, H., *Tramiprosate protects neurons against ischemic stroke by disrupting the interaction between PSD95 and nNOS*. *Neuropharmacology* **2014**, 83, 107-17.

180. Liu, Y.; Jiang, L.; Li, X., *κ-carrageenan-derived pentasaccharide attenuates Aβ25-35-induced apoptosis in SH-SYSY cells via suppression of the JNK signaling pathway*. *Molecular medicine reports* **2017**, 15, (1), 285-290.

181. Gao, Y.; Li, C.; Yin, J.; Shen, J.; Wang, H.; Wu, Y.; Jin, H., *Fucoidan, a sulfated polysaccharide from brown algae, improves cognitive impairment induced by infusion of Aβ peptide in rats*. *Environ Toxicol Pharmacol* **2012**, 33, (2), 304-311.

182. Wang, X.; Yi, K.; Zhao, Y., *Fucoidan inhibits amyloid-β-induced toxicity in transgenic Caenorhabditis elegans by reducing the accumulation of amyloid-β and decreasing the production of reactive oxygen species*. *Food Funct* **2018**, 9, (1), 552-560.

183. Park, S. K.; Kang, J. Y.; Kim, J. M.; Yoo, S. K.; Han, H. J.; Chung, D. H.; Kim, D.-O.; Kim, G.-H.; Heo, H. J., *Fucoidan-Rich Substances from Ecklonia cava Improve Trimethyltin-Induced Cognitive Dysfunction via Down-Regulation of Amyloid β Production/Tau Hyperphosphorylation*. *Mar Drugs* **2019**, 17, (10), 591.

184. Kim, H.; Ahn, J. H.; Song, M.; Kim, D. W.; Lee, T. K.; Lee, J. C.; Kim, Y. M.; Kim, J. D.; Cho, J. H.; Hwang, I. K.; Yan, B. C.; Won, M. H.; Park, J. H., *Pretreated fucoidan confers neuroprotection against transient global cerebral ischemic injury in the gerbil hippocampal CA1 area via reducing of glial cell activation and oxidative stress*. *Biomed Pharmacother* **2019**, 109, 1718-1727.

185. Lee, T. K.; Ahn, J. H.; Park, C. W.; Kim, B.; Park, Y. E.; Lee, J. C.; Park, J. H.; Yang, G. E.; Shin, M. C.; Cho, J. H.; Kang, I. J.; Won, M. H., *Pre-Treatment with Laminarin Protects Hippocampal CA1 Pyramidal Neurons and Attenuates Reactive Gliosis Following Transient Forebrain Ischemia in Gerbils*. *Mar Drugs* **2020**, 18, (1).

186. Liu, Y.; Geng, L.; Zhang, J.; Wang, J.; Zhang, Q.; Duan, D.; Zhang, Q., *Oligo-Porphyran Ameliorates Neurobehavioral Deficits in Parkinsonian Mice by Regulating the PI3K/Akt/Bcl-2 Pathway*. *Mar Drugs* **2018**, 16, (3), 82.

187. Zhang, Z.; Wang, X.; Pan, Y.; Wang, G.; Mao, G., *The degraded polysaccharide from Pyropia haitanensis represses amyloid beta peptide-induced neurotoxicity and memory in vivo*. *Int J Biol Macromol* **2020**, 146, 725-729.

188. Pentón-Rol, G.; Marín-Prida, J.; Pardo-Andreu, G.; Martínez-Sánchez, G.; Acosta-Medina, E. F.; Valdivia-Acosta, A.; Lagumersindez-Denis, N.; Rodríguez-Jiménez, E.; Llópiz-Arzua, A.;
López-Saura, P. A.; Guillén-Nieto, G.; Pentón-Arias, E., Phycocyanin is neuroprotective against global cerebral ischemia/reperfusion injury in gerbils. *Brain Res Bull* 2011, 86, (1-2), 42-52.

190. Souza, R. B.; Frota, A. F.; Sousa, R. S.; Cezario, N. A.; Santos, T. B.; Souza, L. M.; Coura, C. O.; Monteiro, V. S.; Cristino Filho, G.; Vasconcelos, S. M.; da Cunha, R. M.; Aguiar, L. M.; Benevides, N. M., Neuroprotective Effects of Sulphated Agaran from Marine Alga Gracilaria cornea in Rat 6-Hydroxydopamine Parkinson's Disease Model: Behavioural, Neurochemical and Transcriptional Alterations. *Basic & clinical pharmacology & toxicology* 2017, 120, (2), 159-170.

191. Zhou, X.; Yi, M.; Ding, L.; He, S.; Yan, X., Isolation and Purification of a Neuroprotective Phlorotannin from the Marine Algae Ecklonia maxima by Size Exclusion and High-Speed Counter-Current Chromatography. *Mar Drugs* 2019, 17, (4), 212.

192. Dimitrova-Shumkovska, J.; Krstanoski, L.; Veenman, L., Potential Beneficial Actions of Fucoidan in Brain and Liver Injury, Disease, and Intoxication—Potential Implication of Sirtuins. 2020, 18, (5), 242.

193. Yang, W. N.; Chen, P. W.; Huang, C. Y., Compositional Characteristics and In Vitro Evaluations of Antioxidant and Neuroprotective Properties of Crude Extracts of Fucoidan Prepared from Compressional Puffing-Pretreated Sargassum crassifolium. *Mar Drugs* 2017, 15, (6).

194. Tsang, C. K.; Kamei, Y., Sargacuinoic acid supports the survival of neuronal PC12D cells in a nerve growth factor-independent manner. *Eur J Pharmacol* 2004, 488, (1-3), 11-8.

195. Caltagirone, C.; Ferrannini, L.; Marchionni, N.; Nappi, G.; Scapagnini, G.; Trabucchi, M., The potential protective effect of trampirose (homotaurine) against Alzheimer's disease: a review. *Aging clinical and experimental research* 2012, 24, (6), 580-7.

196. Tsolaki, M., Future strategies of management of Alzheimer's Disease. The role of homotaurine. *Hellenic journal of nuclear medicine* 2019, 22 Suppl, 82-94.

197. Oh, J. H.; Kim, E. Y.; Nam, T. J., Phycoerythrin Peptide from Pyropia yezoensis Alleviates Endoplasmic Reticulum Stress Caused by Perfluorooctane Sulfonate-Induced Calcium Dysregulation. *Mar Drugs* 2018, 16, (2).

198. Oh, J. H.; Kim, E. Y.; Nam, T. J., Phycoerythrin-Derived Tryptic Peptide of a Red Alga Pyropia yezoensis Attenuates Glutamate-Induced ER Stress and Neuronal Senescence in Primary Rat Hippocampal Neurons. *Mol Nutr Food Res* 2018, 62, (8), e1700469.

199. Silva, J.; Alves, C.; Pinteus, S.; Mendes, S.; Pedrosa, R., Neuroprotective effects of seaweeds against 6-hydroxidopamine-induced cell death on an in vitro human neuroblastoma model. *BMC Complement Altern Med* 2018, 18, (1), 58-58.

200. Silva, J.; Alves, C.; Freitas, R.; Martins, A.; Pinteus, S.; Ribeiro, J.; Gaspar, H.; Alfonso, A.; Pedrosa, R., Antioxidant and Neuroprotective Potential of the Brown Seaweed Bifurcaria bifurcata in an in vitro Parkinson's Disease Model. *Mar Drugs* 2019, 17, (2).

201. Alghazwi, M.; Smid, S.; Zhang, W., In vitro protective activity of South Australian marine sponge and macroalgae extracts against amyloid beta (Aβ(1-42)) induced neurotoxicity in PC-12 cells. *Neurotoxicology and teratology* 2018, 68, 72-83.

202. Mohibbullah, M.; Hannan, M. A.; Choi, J.-Y.; Bhuiyan, M. M. H.; Hong, Y.-K.; Choi, J.-S.; Choi,
I. S.; Moon, I. S., The Edible Marine Alga Gracilaria chorda Alleviates Hypoxia/Reoxygenation-Induced Oxidative Stress in Cultured Hippocampal Neurons. Journal of medicinal food 2015, 18, (9), 960-971.

203. Yang, Y.; Yang, I.; Cao, M.; Su, Z.-Y.; Wu, R.; Guo, Y.; Fang, M.; Kong, A.-N., Fucoxanthin Elicits Epigenetic Modifications, Nrf2 Activation and Blocking Transformation in Mouse Skin JB6 P+ Cells. AAPS J 2018, 20, (2), 32-32.

204. Oh, J. H.; Nam, T. J., Hydrophilic Glycoproteins of an Edible Green Alga Capsosiphon fulvescens Prevent Aging-Induced Spatial Memory Impairment by Suppressing GSK-3beta-Mediated ER Stress in Dorsal Hippocampus. Mar Drugs 2019, 17, (3).

205. Oh, J. H.; Nam, T. J.; Choi, Y. H., Capsosiphon fulvescens Glycoproteins Enhance Probiotics-Induced Cognitive Improvement in Aged Rats. Nutrients 2020, 12, (3).

206. Nisha, S. A.; Devi, K. P., Gelidiella acerosa protects against Aβ 25-35-induced toxicity and memory impairment in Swiss Albino mice: an in vivo report. Pharm Biol 2017, 55, (1), 1423-1435.

207. Siddiqui, P. J. A.; Khan, A.; Uddin, N.; Khaliq, S.; Rasheed, M.; Nawaz, S.; Dar, A.; Hanif, M., Sargassum swartzii extracts ameliorate memory functions by neurochemical modulation in a rat model. Food Sci Biotechnol 2017, 26, (4), 1055-1062.

208. Choi, J.-Y.; Mohibullah, M.; Park, I.-S.; Moon, I. S.; Hong, Y.-K., An ethanol extract from the phaeophyte Undaria pinnatifida improves learning and memory impairment and dendritic spine morphology in hippocampal neurons. Journal of Applied Phycology 2018, 30, (1), 129-136.

209. Kim, J. H.; Lee, N. S.; Jeong, Y. G.; Lee, J. H.; Kim, E. J.; Han, S. Y., Protective efficacy of an Ecklonia cava extract used to treat transient focal ischemia of the rat brain. Anatomy & cell biology 2012, 45, (2), 103-13.

210. Jiang, R.-w.; Du, X.-g.; Zhang, X.; Wang, X.; Hu, D.-y.; Meng, T.; Chen, Y.-l.; Geng, M.-y.; Shen, J.-k., Synthesis and bioassay of β-(1,4)-D-mannans as potential agents against Alzheimer’s disease. Acta Pharmacol Sin 2013, 34, (12), 1585-1591.

211. Wang, X.; Sun, G.; Peng, T.; Zhang, J.; Huang, X.; Wang, T.; Xie, Z.; Chu, X.; Yang, J.; Wang, H.; Chang, S.; Gong, Y.; Ruan, L.; Zhang, G.; Yan, S.; Lian, W.; Du, C.; Yang, D.; Zhang, Q.; Lin, F.; Liu, J.; Zhang, H.; Ge, C.; Xiao, S.; Ding, J.; Geng, M., Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer’s disease progression. Cell research 2019, 29, (10), 787-803.

212. Xiao, S.; Zhang, Z.; Geng, M.; Disease, G.-S. G. J. C. T. o. A. s., Phase 3 Clinical Trial of a Novel and Multi-targeted Oligosaccharide in Patients with Mildmoderate AD in China. 2018.

213. Davis, G. D.; Vasanthi, A. H., Seaweed metabolite database (SWMD): A database of natural compounds from marine algae. Bioinformation 2011, 5, (8), 361-4.

214. Lei, J.; Zhou, J., A marine natural product database. Journal of chemical information and computer sciences 2002, 42, (3), 742-8.

215. Babu, P. A.; Puppala, S. S.; Aswini, S. L.; Vani, M. R.; Kumar, C. N.; Prasanna, T., A database
of natural products and chemical entities from marine habitat. *Bioinformation* 2008, 3, (3), 142-3.

216. Barbosa, A. J. M.; Roque, A. C. A., Free Marine Natural Products Databases for Biotechnology and Bioengineering. *Biotechnology Journal* 2019, 14, (11), 1800607.

217. Products, D. o. M. N. http://dmnp.chemnetbase.com/faces/chemical/ChemicalSearch.xhtml (May 20, 2020),

218. MarinLit A database of the marine natural products literature. http://pubs.rsc.org/marinlit (May 20, 2020),

219. Keller, T. H.; Pichota, A.; Yin, Z., A practical view of ‘druggability’. *Current opinion in chemical biology* 2006, 10, (4), 357-61.

220. Wale, N.; Karypis, G., Target fishing for chemical compounds using target-ligand activity data and ranking based methods. *J Chem Inf Model* 2009, 49, (10), 2190-2201.

221. Huang, H.; Zhang, G.; Zhou, Y.; Lin, C.; Chen, S.; Lin, Y.; Mai, S.; Huang, Z. J. F. i. c., Reverse screening methods to search for the protein targets of chemopreventive compounds. 2018, 6, 138.

222. Dunkel, M.; Fullbeck, M.; Neumann, S.; Preissner, R., SuperNatural: a searchable database of available natural compounds. *Nucleic Acids Res* 2006, 34, (Database issue), D678-D683.

223. Huang, L.; Xie, D.; Yu, Y.; Liu, H.; Shi, Y.; Shi, T.; Wen, C., TCMID 2.0: a comprehensive resource for TCM. *Nucleic Acids Res* 2017, 46, (D1), D1117-D1120.

224. Ru, J.; Li, P.; Wang, J.; Zhou, W.; Li, B.; Huang, C.; Li, P.; Guo, Z.; Tao, W.; Yang, Y.; Xu, X.; Li, Y.; Wang, Y.; Yang, L., TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. *Journal of cheminformatics* 2014, 6, 13.

225. Pereira, F.; Aires-de-Sousa, J., Computational Methodologies in the Exploration of Marine Natural Product Leads. *Mar Drugs* 2018, 16, (7).

226. Sorokina, M.; Steinbeck, C., Review on natural products databases: where to find data in 2020. *Journal of cheminformatics* 2020, 12, (1), 20.

227. Vitale, R. M.; D’Aniello, E.; Gorbi, S.; Martella, A.; Silvestri, C.; Giuliani, M. E.; Fellous, T.; Gentile, A.; Carbone, M.; Cutignano, A.; Grauso, L.; Magliozzi, L.; Polese, G.; D’Aniello, B.; Defranoux, F.; Felline, S.; Terlizzi, A.; Calignano, A.; Regoli, F.; Di Marzo, V.; Amodeo, P.; Mollo, E., Fishing for Targets of Alien Metabolites: A Novel Peroxisome Proliferator-Activated Receptor (PPAR) Agonist from a Marine Pest. *Mar Drugs* 2018, 16, (11).

228. Chamberlin, S. R.; Blucher, A.; Wu, G.; Shinto, L.; Choonoo, G.; Kulesz-Martin, M.; McWeeney, S., Natural Product Target Network Reveals Potential for Cancer Combination Therapies. 2019, 10, (557).

229. Jung, H. A.; Roy, A.; Choi, J. S., In vitro monoamine oxidase A and B inhibitory activity and molecular docking simulations of fucoxanthin. *Fisheries Science* 2017, 83, (1), 123-132.

230. Paudel, P.; Seong, S. H.; Jung, H. A.; Choi, J. S., Characterizing fucoxanthin as a selective dopamine D(3)/D(4) receptor agonist: Relevance to Parkinson’s disease. *Chemico-biological interactions* 2019, 310, 108757.

231. Paudel, P.; Park, S. E.; Seong, S. H.; Jung, H. A.; Choi, J. S., Bromophenols from Symphyocladia latiuscula Target Human Monoamine Oxidase and Dopaminergic Receptors
for the Management of Neurodegenerative Diseases. *Journal of Agricultural and Food Chemistry* **2020**, *68*, (8), 2426-2436.

232. Floresta, G.; Amata, E.; Barbaraci, C.; Gentile, D.; Turnaturi, R.; Marrazzo, A.; Rescifina, A., A Structure- and Ligand-Based Virtual Screening of a Database of “Small” Marine Natural Products for the Identification of “Blue” Sigma-2 Receptor Ligands. *Mar Drugs* **2018**, *16*, (10).

233. National Food Institute, T. U. o. D. D.; Sá Monteiro, M.; Sloth, J.; Holdt, S.; Hansen, M., Analysis and Risk Assessment of Seaweed. *EFSA Journal* **2019**, *17*, (S2), e170915.

234. Hwang, P. A.; Yan, M. D.; Lin, H. T.; Li, K. L.; Lin, Y. C., Toxicological Evaluation of Low Molecular Weight Fucoidan in Vitro and in Vivo. *Mar Drugs* **2016**, *14*, (7).

235. Li, N.; Zhang, Q.; Song, J., Toxicological evaluation of fucoidan extracted from Laminaria japonica in Wistar rats. *Food Chem Toxicol* **2005**, *43*, (3), 421-6.

236. Chung, H. J.; Jeun, J.; Houng, S. J.; Jun, H. J.; Kweon, D. K.; Lee, S. J., Toxicological evaluation of fucoidan from Undaria pinnatifidain vitro and in vivo. *Phytother Res* **2010**, *24*, (7), 1078-83.

237. Kim, K. J.; Lee, O. H.; Lee, B. Y., Genotoxicity studies on fucoidan from Sporophyll of Undaria pinnatifida. *Food Chem Toxicol* **2010**, *48*, (4), 1101-4.

238. Kim, K. J.; Lee, O. H.; Lee, H. H.; Lee, B. Y., A 4-week repeated oral dose toxicity study of fucoidan from the Sporophyll of Undaria pinnatifida in Sprague-Dawley rats. *Toxicology* **2010**, *267*, (1-3), 154-8.

239. Myers, S. P.; O’Connor, J.; Fitton, J. H.; Brooks, L.; Rolfe, M.; Connellan, P.; Wohlmuth, H.; Cheras, P. A.; Morris, C., A combined phase I and II open label study on the effects of a seaweed extract nutrient complex on osteoarthritis. *Biologics : targets & therapy* **2010**, *4*, 33-44.

240. Myers, S. P.; Mulder, A. M.; Baker, D. G.; Robinson, S. R.; Rolfe, M. I.; Brooks, L.; Fitton, J. H., Effects of fucoidan from Fucus vesiculosus in reducing symptoms of osteoarthritis: a randomized placebo-controlled trial. *Biologics : targets & therapy* **2016**, *10*, 81-8.

241. Weiner, M. L., Food additive carrageenan: Part II: A critical review of carrageenan in vivo safety studies. *Critical reviews in Toxicology* **2014**, *44*, (3), 244-69.

242. Hebar, A.; Koller, C.; Seifert, J. M.; Chabicovsky, M.; Bodenteich, A.; Bernkop-Schnurch, A.; Grassauer, A.; Prieschl-Grassauer, E., Non-clinical safety evaluation of intranasal iota-carrageenan. *PLoS One* **2015**, *10*, (4), e0122911.

243. Beppu, F.; Niwano, Y.; Tsukui, T.; Hosokawa, M.; Miyashita, K., Single and repeated oral dose toxicity study of fucoxanthin (FX), a marine carotenoid, in mice. *The Journal of toxicological sciences* **2009**, *34*, (5), 501-10.

244. Kadekaru, T.; Toyama, H.; Yasumoto, T., Safety Evaluation of Fucoxanthin purified from Undaria pinnatifida</I>. *Nippon Shokuhin Kagaku Kogaku Kaishi* **2008**, *55*, (6), 304-308.

245. Beppu, F.; Niwano, Y.; Sato, E.; Kohno, M.; Tsukui, T.; Hosokawa, M.; Miyashita, K., In vitro and in vivo evaluation of mutagenicity of fucoxanthin (FX) and its metabolite fucoxanthinol (FXOH). *The Journal of toxicological sciences* **2009**, *34*, (6), 693-8.